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The Roles of Nuclear Receptor NR4A1 in Cancer Cell Proliferation and Skeletal
Muscle Differentiation
Abstract
Nuclear receptors (NRs) constitute a major class of drug targets in the treatment of various cancer types.
NRs respond to cellular signals and become activated upon ligand binding to transcriptionally modulate
expression of target genes. NR4A1 (Nur77) is a member of the NR4A family of nuclear receptors and
displays an oncogenic profile in many cancer models. It is often upregulated in adult solid malignancies
and is known to promote cell proliferation and survival. Knockdown studies of NR4A1 in cancer cell lines
results in decreased cell growth and angiogenesis and increased apoptosis, suggesting NR4A1 is an
oncogenic protein. Due to the elevated levels of NR4A1 in cancer, it is important to determine the
regulatory mechanisms behind this expression pattern.
One such mechanism is through microRNAs (miRNAs), which regulate gene expression by binding to the
3ʹUTR of target mRNA and effectively inhibit translation into protein. Prior to
this study, no miRNAs had been identified to directly target NR4A1. By using luciferase reporter assays,
we identified miR-124, miR-15a, and miR-224 as potential NR4A1 regulators. The direct binding of these
miRNAs to their potential seed regions within the 3ʹUTR of NR4A1 was confirmed by mutagenesis of their
respective seed sequences. This abrogated the binding and thereby confirmed the direct targeting of
these miRNAs to these particular sequences. To further study the relationship between NR4A1 and these
miRNAs, we analyzed endogenous expression levels in several pediatric cancer cell lines. NR4A1 was
upregulated in RD, Rh41, and Rh30 rhabdomyosarcoma cells and D341 and Daoy medulloblastoma cells
as well as NB3 neuroblastoma cells. All three miRNAs were downregulated in Daoy cells. Considering that
miR-124 is highly expressed in the brain and is a tumor suppressor, we decided to investigate the
functional significance between NR4A1 and miR-124 in Daoy cells. We found that miR-124 could decrease
NR4A1 mRNA and protein levels as well as the expression of several NR4A1 target genes. Overexpression
of NR4A1 led to enhanced cell viability and proliferation while knockdown resulted in the opposite
phenotype. Furthermore, stable expression of miR-124 in Daoy cells resulted in decreased proliferation
and smaller spheroid formation. Lastly, we examined expression levels in granule neuron precursors
(GNPs), which are the most common cell type in the cerebellum where medulloblastoma arises.
Interestingly, there was an inverse expression pattern in which miR-124 was increased while Nr4a1 was
decreased in the differentiated GNPs, suggesting a potential role for NR4A1 in neuronal development.
In addition to cancer cell proliferation, the role of NR4A1 in skeletal muscle differentiation was also
explored. We found that NR4A1 increased during the differentiation of human LHCN myoblasts, and that
knockdown of NR4A1 impairs differentiation and reduces expression of myogenic markers in LHCN as
well as SkMC, and HSMM primary human skeletal muscle cells. This data agrees with previous studies
performed in mouse models and mouse C2C12 cells showing increased Nr4a1 expression during
differentiation as well as the ability of NR4A1 to enhance muscle mass and myofiber size.
Together, these two studies highlight two different and opposing functional roles of NR4A1 in
medulloblastoma and skeletal muscle. The first study identified three miRNAs capable of directly
targeting and suppressing NR4A1 and also provides a rationale for the use of miRNA mimics as a
potential therapeutic in cancers with high NR4A1 expression. In the second study, we provided evidence
that further confirms the pro-myogenic function of NR4A1 during skeletal muscle differentiation. It is
important to understand this basic biology as it can help further understand and treat diseases related to
muscle such as rhabdomyosarcoma and muscular dystrophy.
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ABSTRACT
Nuclear receptors (NRs) constitute a major class of drug targets in the treatment
of various cancer types. NRs respond to cellular signals and become activated upon
ligand binding to transcriptionally modulate expression of target genes. NR4A1 (Nur77)
is a member of the NR4A family of nuclear receptors and displays an oncogenic profile
in many cancer models. It is often upregulated in adult solid malignancies and is known
to promote cell proliferation and survival. Knockdown studies of NR4A1 in cancer cell
lines result in decreased cell growth and angiogenesis and increased apoptosis, suggesting
NR4A1 is an oncogenic protein. Due to the elevated levels of NR4A1 in cancer, it is
important to determine the regulatory mechanisms behind this expression pattern.
One such mechanism is through microRNAs (miRNAs), which regulate gene
expression by binding to the 3ʹUTR of target mRNA and effectively inhibit translation
into protein. Prior to this study, no miRNAs had been identified to directly target NR4A1.
By using luciferase reporter assays, we identified miR-124, miR-15a, and miR-224 as
potential NR4A1 regulators. The direct binding of these miRNAs to their potential seed
regions within the 3ʹUTR of NR4A1 was confirmed by mutagenesis of their respective
seed sequences. This abrogated the binding and thereby confirmed the direct targeting of
these miRNAs to these particular sequences. To further study the relationship between
NR4A1 and these miRNAs, we analyzed endogenous expression levels in several
pediatric cancer cell lines. NR4A1 was upregulated in RD, Rh41, and Rh30
rhabdomyosarcoma cells and D341 and Daoy medulloblastoma cells as well as NB3
neuroblastoma cells. All three miRNAs were downregulated in Daoy cells. Considering
that miR-124 is highly expressed in the brain and is a tumor suppressor, we decided to
investigate the functional significance between NR4A1 and miR-124 in Daoy cells. We
found that miR-124 could decrease NR4A1 mRNA and protein levels as well as the
expression of several NR4A1 target genes. Overexpression of NR4A1 led to enhanced
cell viability and proliferation while knockdown resulted in the opposite phenotype.
Furthermore, stable expression of miR-124 in Daoy cells resulted in decreased
proliferation and smaller spheroid formation. Lastly, we examined expression levels in
granule neuron precursors (GNPs), which are the most common cell type in the
cerebellum where medulloblastoma arises. Interestingly, there was an inverse expression
pattern in which miR-124 was increased while Nr4a1 was decreased in the differentiated
GNPs, suggesting a potential role for NR4A1 in neuronal development.
In addition to cancer cell proliferation, the role of NR4A1 in skeletal muscle
differentiation was also explored. We found that NR4A1 increased during the
differentiation of human LHCN myoblasts, and that knockdown of NR4A1 impairs
differentiation and reduces expression of myogenic markers in LHCN as well as SkMC,
and HSMM primary human skeletal muscle cells. This data agrees with previous studies
performed in mouse models and mouse C2C12 cells showing increased Nr4a1 expression
during differentiation as well as the ability of NR4A1 to enhance muscle mass and
myofiber size.
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Together, these two studies highlight two different and opposing functional roles
of NR4A1 in medulloblastoma and skeletal muscle. The first study identified three
miRNAs capable of directly targeting and suppressing NR4A1 and also provides a
rationale for the use of miRNA mimics as a potential therapeutic in cancers with high
NR4A1 expression. In the second study, we provided evidence that further confirms the
pro-myogenic function of NR4A1 during skeletal muscle differentiation. It is important
to understand this basic biology as it can help further understand and treat diseases
related to muscle such as rhabdomyosarcoma and muscular dystrophy.
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CHAPTER 1.

INTRODUCTION

Nuclear Receptors
Discovery and classification
Before the word ‘hormone’ was coined in 1905 by Ernest Starling or the word
‘receptor’ by Paul Erhlich in 1907, not much was known about hormones or nuclear
(hormone) receptors [1]. The first NRs cloned were the glucocorticoid and estrogen
receptors in 1985 and 1986, respectively [2, 3], although the estrogen receptor was
originally isolated in 1958 by Elwood Jensen [4]. Preceding the discovery of these
receptors, cortisone, a steroid that binds the glucocorticoid receptor, and thyroxine, an
iodoamino acid that binds the thyroid receptor, were the first ligands to be isolated and
analyzed for their structures in 1926 [5, 6]. Soon after in the 1920s and 1930s, the
pancreatic hormone insulin was characterized along with the steroid hormones estrogen,
testosterone, and progesterone [1]. It is now known that humans have a total of 48
nuclear receptors termed the nuclear receptor superfamily, as listed in Table 1-1 [7].
Over the years as more and more NRs were discovered, there was much confusion
as to the nomenclature of these genes. Hence, in 1999 a group of scientists came together
to formally name these receptors based on their phylogeny [8]. These 48 nuclear
receptors have since been classified into 6 subfamilies, with the first subfamily, the
thyroid hormone receptor-like family, having 8 subgroups. These groupings are based on
sequence homology [9-11]. There are also several ways of referring to each receptor.
Other than spelling out the full name of the receptor, it can also be identified by its
nuclear receptor nomenclature committee (NRNC) symbol, its abbreviation, or its gene
name. For example, nerve growth factor-induced clone B, a member of the nerve growth
factor IB-like subgroup, is part of the 4th subgroup and is the first member of its family
and therefore has the NRNC symbol NR4A1. Its abbreviation is Nur77, although it has
many other common names including NGFIB, NR4A1, and TR3, and lastly its gene
symbol is NR4A1.
They can also be grouped into liganded NRs, adopted NRs, and orphan NRs.
Liganded NRs are those which have a known ligand, such as the estrogen receptor with
estrogen acting as its ligand. On the other hand, orphan receptors have no known
endogenous ligand, such as COUP-TF. And as the name implies, adopted receptors are
those which were once orphans but now have an identified ligand, such as FXR found to
be activated by bile acids [12]. The initial discovery of nuclear receptors was based on
using ligands to identify the receptor they bind to, but as technology improved it became
possible to discover receptors without knowing their ligands, hence the appearance of
adopted nuclear receptors.
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Table 1-1.

Nuclear receptor superfamily.

Subfamily

Group

Name

Abbreviation

Ligand

Disease implicated

Therapeutic drug name

Thyroid
hormone
receptor-like

Thyroid hormone
receptor

thyroid hormone
receptor α

TRα

thyroid hormone

evothyroxine,
levothyroxine,
liothyronine

TRβ

thyroid hormone

Retinoic acid receptor

thyroid hormone
receptor β
Retinoic acid receptor α

thyroid resistance
syndrome, thyroid
cancer
hypercholesterolemia

RARα

retinoic acids

acute promyelocytic
leukemia, kidney
disease, Alzheimer's
disease, skin diseases,
cancers

all-trans retinoic acid
(ATRA)

Retinoic acid receptor β

RARβ

retinoic acids

Retinoic acid receptor γ

RARγ

retinoic acids

Peroxisome
proliferator-activated
receptor α
Peroxisome
proliferator-activated
receptor β/δ
Peroxisome
proliferator-activated
receptor γ

PPARα

Fatty acids and
prostaglandins

fibrates (clofibrate,
gemfibrozil, fenofibrate)

PPARβ/δ

Fatty acids and
prostaglandins

PPARγ

Fatty acids and
prostaglandins

Type II diabetes,
atherosclerosis, obesity,
hyperlipidemia
Type II diabetes,
atherosclerosis, obesity,
hyperlipidemia
Type II diabetes,
atherosclerosis,
obesity, hyperlipidemia,
anaplastic cancer

Reverse-Erb α

REV-ERBα

heme

Reverse-Erb β

REV-ERBβ

heme

RAR-related orphan
receptor α
RAR-related orphan
receptor β
RAR-related orphan
receptor γ

RORα

cholesterol and
ATRA
cholesterol and
ATRA
cholesterol and
ATRA

Peroxisome
proliferator-activated
receptor

Rev-ErbA
RAR-related orphan
receptor

RORβ
RORγ

2

atherosclerosis

thiazolidinediones
(roziglitazone,
pioglitazone,
perflurooctanoic acid),
RS544

Table 1-1.
Subfamily

Continued.
Group

Name

Abbreviation

Ligand

Disease implicated

Therapeutic drug name

Liver X receptor-like

Liver X receptor α

LXRα

oxysterols

TO901317, GW3965, NAcylthiadiazolines

Liver X receptor β

LXRβ

oxysterols

Farnesoid X receptor α

FXRα

oxysterols, bile acids

Alzheimer's disease,
atherosclerosis,
dyslipidemia, nonalcoholic fatty liver
disease, breast cancer
atherosclerosis,
dyslipidemia
cholestasis,
hypercholesterolemia,
biliary cirrhosis, nonalcoholic fatty liver
disease

Farnesoid X receptor β

FXRβ

oxysterols

Vitamin D receptor

VDR

vitamin D and
lithocholic acid

calcitriol, doxercalciferol

Pregnane X receptor

PXR

xenobiotics and
endobiotics

Constitutive androstane
receptor
Hepatocyte nuclear
factor-4 α
Hepatocyte nuclear
factor-4 γ
Retinoid X receptor α

CAR

xenobiotics,
androstane
fatty acids, palmitic
acid
fatty acids

hypocalcemia,
osteoporosis, renal
failure, colon cancer,
diabetic nephropathy,
hypertension,
atherosclerosis
cholestatic liver disease,
hyperbilirubinemia, liver
injury, cancer
cholestatic liver disease,
type II diabetes
diabetes

metabolic diseases,
cancers (skin cancer,
cutaneous T cell
lymphoma)

bexarotene

Vitamin D receptorlike

Retinoid X
Receptor-like

Hepatocyte nuclear
factor-4
Retinoid X receptor

HNF4α
HNF4γ
RXRα

9-cis retinoic acid
and docosahexanoic
acid

3

guggulsterone,
chenodeoxycholic acid,
fexaramine

rifampicin
phenobarbitol

Table 1-1.
Subfamily

Continued.
Group

Testicular receptor
TLX/PNR

COUP/EAR

Estrogen
Receptor-like

Estrogen receptor

Estrogen related
receptor

Name

Abbreviation

Ligand

Retinoid X receptor β

RXRβ

Retinoid X receptor γ

RXRγ

9-cis retinoic acid and
docosahexanoic acid
9-cis retinoic acid and
docosahexanoic acid

Testicular receptor 2

TR2

Testicular receptor 4

TR4

Tailless homolog
orphan receptor
Photoreceptor cellspecific nuclear
receptor
Chicken ovalbumin
upstream promotertranscription factor I
Chicken ovalbumin
upstream promotertranscription factor II
V-erbA-related

TLX

Estrogen receptor-α

ERα

estrogens

Estrogen receptor-β

ERβ

estrogens

Estrogen-related
receptor-α
Estrogen-related
receptor-β

ERRα

Disease implicated

Therapeutic drug
name

breast cancer, ovarian
cancer, prostate cancer,
colon cancer,
osteoporosis
breast cancer, ovarian
cancer, prostate cancer,
colon cancer,
osteoporosis

tamoxifen, raloxifene,
gen-estein,
diethylstilbestrol,
equineestrogens

PNR
COUP-TFI
COUP-TFII
EAR-2

ERRβ
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Table 1-1.
Subfamily

Nerve
Growth
Factor IBlike

Steroidogenic
Factor-like
Germ Cell
Nuclear
Factor-like

Continued.
Group

Name

Abbreviation
ERRγ

3-ketosteroid receptors

Estrogen-related
receptor-γ
Glucocorticoid receptor

NGFIB/NURR1/NOR1

SF1/LRH1

GCNF

Ligand

Disease implicated

Therapeutic drug
name

GR

glucocorticoids,
cortisol

dexamethasone,
cortisol, prednisolone,
RU486

Mineralocorticoid
receptor

MR

mineralocorticoids
and glucocorticoids
(aldosterone)

Progesterone receptor

PR

progesterone

Androgen receptor

AR

Nerve growth factor
induced gene B

NGFIB

androgens,
testosterone
unsaturated fatty
acids

inflammatory diseases
(Inflammatory bowel
syndrome, auto immune
disorder, rheumatoid
arthritis, gout, asthma,
cancer)
heart failure,
hypertension,
cardiovascular disease,
kidney disease
breast cancer,
endometriosis
prostate cancer,
osteoporosis

Nuclear receptor
related 1
Neuron-derived orphan
receptor 1
Steroidogenic factor 1

NURR1

SF1

phosphatidylinositols

Liver receptor
homolog-1
Germ cell nuclear
factor

LRH-1

phosphatidylinositols

Parkinson's disease

NOR1

GCNF

5

spironolactone,
eplerenone
RU486
flutamide, bicalutamide

Table 1-1.

Continued.

Subfamily

Group

Name

Abbreviation

Miscellaneous

DAX/SHP

Dosage-sensitive sex
reversal, adrenal
hypoplasia critical
region, on chromosome
X, gene 1
Small heterodimer
partner

DAX1

SHP

Ligand

Disease implicated

obesity
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Therapeutic drug
name

Structure and function
Structure. By definition, nuclear receptors are also classified as transcription
factors, meaning they can bind the promoters of their target genes to modulate gene
expression. The typical structure of a nuclear receptor consists of a well-conserved DNAbinding domain (DBD), a moderately-conserved C-terminal ligand binding domain
(LBD), and a highly variable N-terminal region containing a ligand-independent
transactivation domain called Activation Function 1(AF-1) as depicted in Figure 1-1A
[3, 10, 13]. The N-terminal region interacts with coregulatory proteins such as
coactivators that enhance the transcription of NR target genes [14]. A closer look at the
DBD reveals two zinc-finger domains as well as the P-box, which is a motif involved in
DNA-binding specificity as well as dimerization with other nuclear receptors as
homodimers or heterodimers. In addition to the promoter region, nuclear receptors may
also bind enhancer and intronic regions of target genes. Nuclear receptors can bind to
these regions, or more specifically their response elements, either as monomers,
homodimers, or heterodimers, where heterodimers typically include binding with RXR
[14]. Orphan receptors typically bind as monomers such as the NR4A family. However,
there are two nuclear receptors, DAX1 and SHP, that surprisingly do not contain a DBD
and mainly act as corepressors [15]. There is a flexible hinge region positioned between
the DBD and LBD that contains the nuclear localization signal (NLS) responsible for
facilitating the import of the receptor inside of the nucleus. The LBD is the largest
domain and as its name implies, its function is dependent on the binding of small
lipophilic ligands in its hydrophobic ligand binding pocket (LBP) [16]. Although the
structure of the LBD is well conserved, the LBP can greatly vary in size. For example,
some nuclear receptors such as SF-1 have a large LBP of about 1600 Å3, while some
orphan receptors completely lack an LBP [15, 17, 18]. For instance, the orphan receptor
NR4A2 contains bulky hydrophobic amino acid side chains in place of its LBP [18]. In
addition to the LBP, the LBD also contains a dimerization interface and an additional
transactivation domain called Activation Function 2 (AF-2), which interacts with and
recruits coregulators and also contains a second NLS [19].
Function. Nuclear receptors function to regulate and facilitate a wide variety of
biological processes including metabolism, reproduction, development, aging, and
homeostasis [20]. Many of these processes are dependent upon ligands to activate their
respective nuclear receptors, which in turn act as intermediates to confer signals to
downstream events [19]. Ligands can include a plethora of signaling molecules such as
hormones, fatty acids, xenobiotics, cholesterol, vitamin D, steroids, and retinoids [14,
21]. In the case of orphan receptors, which account for about half of all nuclear receptors,
these can be induced by many factors such as stress, cytokines, and mitogens [14].
There are three main levels to nuclear receptor function; repression, derepression,
and transcriptional activation [19]. In the absence of a ligand, nuclear receptor activity is
suppressed by the binding of a corepressor complex, which typically contains histone
deacetylase (HDAC) activity. These corepressor complexes commonly contain the
subunits SMRT/NCoR2 or NCoR1, which directly bind the receptor [14]. Ligand binding
can occur in either the cytoplasm or the nucleus, and receptors bound by ligands in the

7

Figure 1-1. The structure and function of liganded and orphan nuclear receptors.
(A) Typical nuclear receptors consist of a DNA-binding (DBD) and ligand-binding
domain (LBD) and two transactivation function domains (AF-1 and AF-2) that recruit
coregulators. (B) Upon activation by various stimuli, nuclear receptors will
heterodimerize and bind to their target genes in conjunction with recruitment of
coactivators (SRC-1 and CBP/p300) and release of corepressor (NCoR/SMRT).
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cytoplasm will translocate to the nucleus [22]. Upon ligand binding, the nuclear receptor
undergoes a conformational change and derepression occurs in which the corepressor
complex is replaced with a coactivator complex containing histone acetyltransferase
(HAT) activity. This HAT activity allows for increased transcriptional activity via
chromatin decondensation. In the last stage of nuclear receptor function, the coactivator
complex is replaced by another coactivator complex and the nuclear receptor is now able
to bind with the promoter of its target gene to induce transcriptional activation of that
gene via recruitment of transcriptional machinery such as RNA polymerase II as shown
in Figure 1-1B [14, 15, 23]. More than 350 coactivators have been identified, including
the more common ones like steroid receptor coactivator 1 (SRC-1), steroid receptor
coactivator-2 (SRC-2), p300, and cAMP response element-binding protein (CBP) that are
likely among the first to be recruited by nuclear receptors [14, 15, 24-26]. On the other
hand, nuclear receptors may mediate repression of target gene expression by recruiting
corepressors such as the nuclear receptor corepressor (NCoR), silencing mediator for
retinoid and thyroid hormone receptors (SMRT), and histone deacetylase 3 (HDAC3)
[27-30]. Nuclear receptors can also mediate gene repression by interacting with other
transcription factors including activation protein-1 (AP-1) and nuclear factor kappa B
(NF-kB) [31, 32]. Typically, unliganded nuclear receptors repress their target genes,
while liganded receptors mediate activation of their target genes. Of course, this is a
simplistic description of nuclear receptor function. Some nuclear receptors such as
orphan receptors may not follow these steps since they may or may not be activated by a
ligand [19]. Instead, they may be constitutively active such as the orphan nuclear receptor
NR4A1 [33].
In addition to their transcriptional activity, nuclear receptors can also interact with
other signaling pathways to impose negative or positive effects on their downstream
signaling. Their activity and function can also be affected by post-translational
modifications such as phosphorylation, acetylation, methylation, sumoylation, and
ubiquitination [15, 34-37]. These interactions can also be dependent on the cell and tissue
type.
Role in cancer
Nuclear receptors are molecular targets for approximately 13% of FDA-approved
drugs [38], and inhibiting this receptor signaling has proved to be beneficial in treating
cancer. Since nuclear receptors play a variety of vital roles, disruption or deregulation of
their functions can lead to serious consequences. However, their ability to bind ligands
makes them therapeutic targets in certain diseases and cancers. Agonists (molecules that
enhance receptor function) and antagonists (molecules that disrupt or inhibit receptor
function) can play important roles in drug discovery. Certain compounds with
agonist/antagonist properties are classified as selective nuclear receptor modulators
(SNuRMs), which act as ligands but differ in their activities from the natural endogenous
ligands [15, 20]. More specifically, there are classes of compounds for certain receptors
such as selective estrogen receptor modulators (SERMs) for ER, selective androgen
receptor modulators for AR, and selective peroxisome proliferator-activated receptor
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modulators for PPAR [39]. The more common nuclear receptors targeted in cancer
therapy are the estrogen receptor (ER) in breast cancer, the androgen receptor (AR) in
prostate cancer, the retinoic acid receptor (RAR) in acute promyelocytic leukemia [15],
and the vitamin D receptor in breast and colon cancer.
In ER-positive breast cancer, estrogen signaling has been found to promote tumor
growth and cancer progression, and treatment with SERMs is used to block this
signaling. These modulators function by affecting the recruitment of certain coactivators
and corepressors in a tissue-dependent manner [40-42]. For example, the SERMs
tamoxifen and raloxifene increase corepressor recruitment in mammary cells, resulting in
inhibition of estrogen signaling and decreased breast cancer growth. On the other hand,
tamoxifen acts as an agonist in endometrial cells and mediates coactivator recruitment,
leading to a higher risk of endometrial cancer [43]. However, raloxifene does not have
this agonistic effect in endometrial cells. This is most likely due to preferential binding of
coregulators to the AF-1 domain depending on certain factors such as tissue and cell type
[44-48]. SERMs can also act as agonists in other tissues including bone, uterine, and
cardiovascular tissue [49, 50]. This kind of tissue selectivity can be beneficial since
estrogen signaling can be inhibited in breast cancer while still allowing for normal
function in other tissues. This can also be useful in the case of osteoporosis in which
raloxifene exerts protective effects while avoiding the increased risk of endometrial
cancer that could result from tamoxifen treatment in menopausal women [20, 51].
Another major nuclear receptor being targeted in disease is the glucocorticoid
receptor (GR) by dexamethasone and prednisolone in inflammatory diseases such as
rheumatoid arthritis, immunological disorders, and cancer [20]. These synthetic ligands
function as agonists of GR and enhance its ability to disrupt NF-kB and AP-1 activities,
leading to decreased proinflammatory cytokines and tumor necrosis factor-α, and
ultimately resulting in reduced inflammation [52-54]. However, continued treatment with
dexamethasone and prednisolone can lead to serious side-effects including diabetes and
osteoporosis [55].
Additional receptor targets include PPARα by fibrates (clofibrate, gemfibrozil,
fenofibrate) in hyperlipidemia, PPARγ by thiazolidinediones (roziglitazone, pioglitazone,
perflurooctanoic acid) in type II diabetes, RXR by bexarotene and alitretinoin in cancer,
RAR by all-trans retinoic acid (ATRA) in acute promyelocytic leukemia, and AR by
flutamide and bicalutamide in prostate cancer [15, 56-60]. The xenobiotic receptors CAR
and PXR can also play a role in cancer by mediating the metabolism of cancer drugs and
drug resistance. PXR is commonly used in the pharmaceutical industry to identify
dangerous drug-drug interactions when screening for new cancer therapies [61].
Furthermore, agonists of PXR have therapeutic potential in treating cholestatic liver
disease and preventing hyperbilirubinemia [22, 62]. Future drug targets include FXR in
nonalcoholic steatohepatitis and cholestatic liver disease and LXR in atherosclerosis and
Alzheimer’s disease by using agonists of these receptors [30, 61, 63]. Many other nuclear
receptors are therapeutic targets in various diseases as listed in Table 1-1 [59, 64, 65].
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NR4A Family
Discovery
The NR4A family consists of NR4A1 (Nur77, NGFI-B, TR3), NR4A2 (Nurr1),
and NR4A3 (Nor-1). They were first characterized as immediate-early response genes
induced by nerve growth factor in PC12 cells [66, 67]. NR4A1 was first isolated in 1989
by Chang et al. from human prostate in which they found that NR4A1 was a 64 kDA
receptor protein that could bind to DNA [68]. This was following the discovery of Nr4a1
in the mouse since Chang et al. noted that human NR4A1 had 86% nucleotide and 91%
amino acid sequence homology to mouse Nr4a1 [68]. Shortly thereafter, Nr4a2 was
identified and cloned from a mouse brain cDNA library by Law et al. and subsequently
from fetal human tissue [69-72]. Nr4a2 was found to be highly expressed in the brain
compared to other tissues, suggesting an important role for NR4A2 in the central nervous
system [69]. Lastly, Nr4a3 was first identified in forebrain neuronal cells that were
undergoing apoptosis. NR4A3 appropriately stands for neuron derived orphan receptor
and was found to encode a 68 kDa protein [73].
Structure and function
Structure. As mentioned, the NR4A family has been classified as orphan
receptors due to the lack of endogenous ligands. However, a recent report claims they are
no longer orphans since there are both synthetic and natural compounds that have been
shown to bind the LBD of all three NR4As [74]. Additionally, unsaturated fatty acids
(UFAs) have been found to act as natural endogenous ligands by binding to the LBD of
NR4A1 and NR4A2 [75, 76]. Interestingly, the LBDs of NR4A1 and NR4A3 contain
hydrophilic surfaces as opposed to the hydrophobic LBP of liganded nuclear receptors
[77, 78]. In addition, the LBDs of the NR4A family completely lack an LBP and classical
coactivator binding site and instead have bulky hydrophobic side chains in place of an
LBP where agonists would normally bind [18, 79]. For this reason, it was believed there
could be no ligand for the NR4As, though this theory has been disproven by the
discovery of small-molecule NR4A1 agonists [75]. Since NRs commonly undergo
conformational changes upon ligand binding, it is possible that the NR4As reveal a
binding pocket in response to ligand interactions. This was proven to be true for NR4A1
in which the UFA arachidonic acid induced a conformational change, allowing it to bind
to the LBD of NR4A1 [75]. In addition, arachidonic acid was found to preferentially bind
to NR4A1 oligomers as opposed to monomers and appeared to stabilize these oligomers
[75].
In terms of sequence homology between the NR4A members, their DBDs and
LBDs are well conserved with about 91-95% homology in the DBD and about 60% in the
LBD, however the N-terminal containing the AF-1 domain is highly divergent [70, 80,
81]. This higher level of variation within the AF-1 domain likely recruits different
cofactors for each NR4A in response to stimuli, which may explain the differential

11

binding of the NR4As to their target gene promoters, thereby resulting in the unique
responses and functions of each NR4A receptor. More specifically, cofactors have been
shown to bind NR4A1 protein between helices 11 and 12 in a hydrophobic region [33,
82, 83]. In terms of the NR4A1 gene structure, it is known to have seven exons, with the
AF-1 domain in exon 2, the DBD in exons 3 and 4, and the LBD in exons 5 to 7 [70]. The
recruitment of coregulators has been shown to involve the AF-1 domain to mediate
NR4A-dependent transcription [33, 77, 78, 84, 85].
Function. Like all nuclear receptors, the NR4As function as transcription factors
and bind the promoters of their target genes to modulate their expression in response to
certain stimuli. Previously characterized as orphans, it was thought that they act
independently of ligands to constitutively modulate gene expression [33, 81, 86-88],
however this may no longer be the case since ligands such as UFAs have been discovered
to bind the LBD of NR4A1 [75]. They can bind as monomers, homodimers, or
heterodimers with each other or with RXR [81, 89-92]. The specific sequence they bind
as monomers is called the NGFI-B response element (NBRE) and consists of 5’A/TAAAGGTCA [93-95]. However as homodimers and NR4A heterodimers, they bind
the Nur-responsive element (NurRE), which consists of a sequence motif found naturally
occurring in the pro-opiomelanocortin (POMC) promoter [90]. Of the NR4A family, only
NR4A1 and NR4A2 form heterodimers with RXR, which bind to the retinoic acid
response element DR5 to mediate the function of RXR in retinoid signaling [91, 92].
The NR4A family is classified as immediate early response genes and can be
induced by a wide variety of physiological signaling molecules to mediate their functions
in proliferation, metabolism, inflammation, differentiation, apoptosis, survival, and DNA
repair, among other functions [33, 96, 97]. They have an innate ability to respond quickly
to these various stimuli, which include growth factors, stress, fatty acids, hormones,
cytokines, neurotransmitters, prostaglandins, phorbol esters, calcium, and various
apoptotic signals [33, 98-109]. In addition, they can also be induced by membrane
depolarization, magnetic fields, and mechanical stress [33, 104, 110-112]. Importantly,
the effects of the NR4A family are extremely context dependent and can vary depending
on the specific tissue and cell type as well as experimental conditions. Moreover, their
functions are heavily influenced by their expression levels, subcellular localization,
posttranslational modifications, interactions with other transcription factors, and crosstalk
with many signaling pathways [97].
Physiological roles
Main functions. The NR4A family is expressed in a variety of tissues, mainly in
those that require higher levels of metabolism and energy. These include skeletal muscle,
adipose, kidney, liver, T-cells, heart, and the brain [33, 92, 113-116]. The first major
function identified for NR4A1 was its requirement for T-cell receptor (TCR)-mediated
apoptosis in immature thymocytes and T-cell hybridomas [117, 118]. Both NR4A1 and
NR4A3 are highly expressed during TCR-mediated cell death [117, 118], and inhibiting
NR4A1 effectively blocks apoptosis in T-cell hybridomas. The lack of NR4A1 in
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transgenic mice can also prevent the process of negative selection [119, 120]. In contrast,
the presence of wild type Nr4a1 or Nr4a3 in mice enable cell death in thymocytes,
resulting in reduced numbers of thymocytes and mature T cells [119-121]. A proposed
mechanism by which NR4A1 mediates this process is via transcriptional activation of
pro-apoptotic genes including Fas-ligand (FasL) [122]. In addition, both NR4A1 and
NR4A3 may localize to the mitochondria and interact with Bcl-2 to induce apoptosis
during the negative selection of T cells [97, 123]. Furthermore, calcium signaling was
also found to be required for NR4A1-mediated apoptosis in T cells [124].
Compared to NR4A1, not as much is known about the physiological functions of
NR4A2 and NR4A3. However, it is known that NR4A2 plays an important role in the
synthesis of dopamine by mediating the transcriptional activation of tyrosine
hydroxylase, an enzyme essential for dopamine synthesis [125]. Furthermore, NR4A2 is
crucial to the normal development of the midbrain by ensuring the proper synthesis of
dopaminergic neurons and facilitating neurotransmitter identity [126]. Interestingly,
NR4A2 has been implicated in Parkinson’s disease due to genetic mutations [127].
Neurological functions. In addition to the role of NR4A2 in dopamine synthesis,
the NR4As appear to have neuroprotective functions as well as roles in learning as they
are induced in the hippocampus during fear conditioning in mice [128]. In addition,
NR4A1 was found to be required for object location while NR4A2 was important for
recognition, long term memory, and object location [129]. NR4A1 has also been
implicated in synaptic remodeling as well as a disease resulting from antipsychotic drugs
[74, 130, 131]. Furthermore, exogenous NR4A1 expression can mediate the repair of
damaged neurons after stroke wherein NR4A1 is normally decreased in neural cells
lacking oxygen and glucose [132].
Inflammation and metabolism. The NR4A family has been found to play roles
in steroidogenesis by regulating the expression of genes involved in the hypothalamicpituitary-adrenal (HPA) axis, a complex network of glands important for many bodily
functions including digestion, mood, and the immune system [133-135]. For example,
corticotropin releasing hormone (CRH) and POMC expression are enhanced by NR4A1,
resulting in activation of the HPA axis and downstream adrenal glucocorticoid synthesis
[135]. The NR4As may also have roles in muscle, adipose, and macrophages as they are
induced by various stimuli in these tissues. For example, all three NR4A receptors are
rapidly induced by lipopolysaccharide (LPS) and more slowly induced by IFNγ in
macrophages while only NR4A1 expression is enhanced by oxidized lipids and cytokines
in these cells [136, 137]. Although NR4A1 is induced by inflammatory stimuli, it appears
to play a protective role during inflammation as demonstrated by its involvement in Tcell development, Treg cell differentiation, and its anti-inflammatory effects in
macrophages [138-140].
The NR4As are also induced in skeletal muscle during recovery from intense
exercise [141]. NR4A1 is important for energy expenditure since knockdown of NR4A1
in C2C12 skeletal muscle cells resulted in decreased expression of genes involved in
lipolysis and lipid homeostasis [142], suggesting a role for NR4A1 in treating obesity.
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Similarly, the NR4As are induced during the differentiation of adipocytes, however their
expression does not appear to be a requirement for differentiation to occur [96, 143].
These studies indicate that the NR4A family is important in regulating lipid and glucose
metabolism, implicating them in the treatment of metabolism disorders.
Furthermore, the NR4A family was found to be upregulated in the livers of type I
and type II diabetic mice [144, 145]. Knockout of NR4A1 in the liver of type II diabetic
mice brought the elevated levels of glucose back to almost normal levels and also
resulted in decreased expression of gluconeogenic genes [144, 145]. Consistent with this
finding, overexpression of NR4A1 induced genes involved in gluconeogenesis and
enhanced hepatic glucose production in mice [96]. NR4A1 overexpression can also
increase LDL cholesterol and decrease HDL cholesterol while reducing triglyceride
levels in the liver [146]. Other studies have shown that NR4A1-deficient mice develop
insulin resistance in their skeletal muscle when fed a high-fat diet [147]. These mice also
have decreased gene expression related to glucose utilization in skeletal muscle, whereas
NR4A1 overexpression in C2C12 cells results in increased expression of genes involved
in glucose and glycogen metabolism [147, 148]. This indicates a role for the NR4A
family in the promotion of type II diabetes.
Cardiovascular system. In addition, the NR4As play roles in energy homeostasis
and the vascular system. All three NR4As had increased expression in brown adipose
tissue (BAT) during cold exposure, and NR4A1 is induced after β-adrenergic stimulation
in brown adipocytes, although Nr4a1 deficient mice do not display abnormal
nonshivering thermogenesis [149]. This lack of NR4A1 may be compensated by the
potential redundancy of NR4A3 since NR4A3 is also induced in brown fat during cold
exposure [149]. Interestingly, tissue-specific knockdown of Nr4a3 in the third cerebral
ventricle in mice resulted in decreased food consumption and body weight, suggesting a
role for the NR4As in energy homeostasis by affecting food intake [96]. In terms of the
vascular system, the NR4As are expressed in atherosclerotic lesions and have been
shown to regulate genes involved in vascular remodeling processes such as proliferation
and inflammation [96]. NR4A1 appears to play a protective role in cardiovascular disease
since mice fed a high fat diet experienced decreases in atherosclerotic plaque formation,
inflammation, and hepatic lipid deposition in response to NR4A1 overexpression [150152]. In contrast, Nr4a3 knockdown in mice decreases hypercholesterolemia-induced
atherosclerosis, suggesting that NR4A3 may promote atherosclerosis [153].
NR4A knockout mice. Surprisingly, NR4A1-null mice do not display abnormal
thymic and peripheral T cell death [133, 154]. Overall, they appear healthy with no
noticeable phenotype or developmental problems [154]. The hypothalamic and pituitary
systems also appear to function normally, as well as steroidogenesis [33, 133]. One
explanation is the possible functional redundancy between the NR4A family wherein the
other members may compensate for the lack of NR4A1. For example, it is known that
NR4A3 is also capable of pro-apoptotic activity in thymocytes, and NR4A2 and NR4A3
also play roles in the HPA axis that could regulate HPA-related genes in place of NR4A1
[33, 123, 134, 135, 154, 155]. However, mice with both Nr4a1 and Nr4a3 knocked out
quickly develop acute myeloid leukemia (AML) and die within 2 to 4 weeks postnatally
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[156]. As a result of this double knockout, there was increased accumulation of
hematopoietic stem cells. Expression of NR4A1 and NR4A3 was also found to be
decreased in patients with AML [156].
Interestingly, mice that lack Nr4a2 develop to full-term but die at birth, seemingly
due a defect in respiratory function. However, others report it is due to the lack of
dopaminergic neurons in the midbrain with the observation of abnormal movements such
as difficulty turning when the mice were placed on their backs as well as the inability to
suckle [126, 157, 158]. Finally, Nr4a3 knockout mice exhibit inner ear defects with
impaired bi-directional circling behavior, which was associated with decreased
endolymphatic fluid space in the ear canals [159, 160]. In addition, Nr4a3-null mice are
more susceptible to limbic seizure activity due to excitotoxic glutamate receptor agonists
[160]. In contrast, another study found that mice lacking Nr4a3 die around embryonic
day 8.5 (E8.5) due to incomplete gastrulation [161].
Apoptotic function
Of interest is the translocation function of NR4A1 from the nucleus to the
mitochondria to induce apoptosis. Although it appears the main function of NR4A1 is to
exert pro-oncogenic and anti-apoptotic effects in cancer cell lines, there are several
instances in which this is not the case. For example in lung and other cancer cell lines,
addition of the retinoid CD437 (AHPN) induces apoptosis in a NR4A1-dependent
manner (Figure 1-2) [162-170]. Many other stimuli have also been shown to induce
nuclear export of NR4A1 to mediate apoptosis, including 5-fluorouracil, viruses, phorbol
ester (TPA), butyrate, cadmium, and cytosporone B (Csn-B), among many others listed in
Table 1-2 [67]. These pro-apoptotic compounds may act by either inducing NR4A1
expression or by directly binding to NR4A1. For example, one study shows that the
natural product Csn-B (derived from endophytic fungi) is able to directly interact with the
LBD of NR4A1 to mediate NR4A1-dependent apoptosis through multiple mechanisms,
including both transcription-dependent and -independent functions (Figure 1-2) [171,
172]. Csn-B treatment of gastric cancer cells resulted in enhanced NR4A1 expression,
which was due in part to autoregulation in which NR4A1 was able to bind its own
promoter to induce expression [171]. NR4A1 was also found to transcriptionally decrease
the antiapoptotic protein BRE in response to Csn-B [172-174]. On the other hand, Csn-B
induced translocation of NR4A1 to the mitochondria prior to activation of the apoptotic
cascade [171]. This was the first evidence of a molecule that could act as a ligand to bind
and activate NR4A1.
The mechanism by which NR4A1 mediates apoptosis involves directly binding to
the anti-apoptotic protein Bcl-2 at the mitochondria and converting it to a pro-apoptotic
protein. This conversion involves a conformational change of Bcl-2 that reveals its proapoptotic BH3 (Bcl-2 homology) domain [175]. Subsequently, cytochrome c is released
and the intrinsic apoptotic cascade is evoked [168]. In addition to the mitochondria,
NR4A1 may also localize to the endoplasmic reticulum (ER) to mediate apoptosis.
Treatment of neuroblastoma cells with retinoid-related compound CD437 (AHPN)
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Figure 1-2. NR4A1 is induced by cytotoxic agents to mediate cell death.
NR4A1 can induce apoptosis in response to apoptotic compounds by either translocating
to the mitochondria or to the endoplasmic reticulum and converts Bcl-2 to a proapoptotic
protein. NR4A1 can also mediate apoptosis by transcriptionally activating genes involved
in the cell death program.
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Table 1-2.
Compounds and apoptotic stimuli that induce Nur77 to mediate cell
death, mainly through mitochondrial localization.
Inducer
N-butylidenephthalide (BP)
di-n-butyltin dichloride (DBTC) and tri-n-butyltin
chloride (TBTC)
Synthetic chenodeoxycholic acid derivatives
Cisplatin
Butyrate
Sulindac
5-fluorouracil
Phorbol ester 12- O-tetradecanoyl phorbol-13-acetate
(TPA)
Calcium ionophore A23187
Etoposide VP-16
AHPN analog 6-[3-(1-adamantyl)-4- hydroxyphenyl]-3chloro-2-naphthalenecarboxylic acid (MM11453)
Retinoid (Z)-4- [2-bromo-3-(5,6,7,8-tetrahydro3,5,5,8,8- pentamethyl-2naphthalenyl)propenoyl]benzoic acid (MM11384)
Sindbis virus
Insulin-like growth factor-binding protein-3 (IGFBP-3)
Shikonin derivatives
Cytosporone B (Csn-B) and related analogues
9-cis-retinoic acid
Cadmium
CD437 (AHPN)
C-DIMs
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Model system
HCC
Rat thymocytes

References
[176]
[177]

Gastric cancer
Ovarian cancer
Colon cancer
Colon cancer
Colon cancer
Prostate and gastric cancer

[178]
[179]
[180]
[180]
[180]
[168, 181]

Prostate cancer cells
Prostate and gastric cancer
Prostate cancer

[168]
[168, 181]
[168]

Prostate cancer

[168]

Primary B cells
Prostate cancer
Lung and cervical cancer
Gastric cancer
Gastric cancer
Lung cancer
Neuroblastoma and
esophageal squamous
carcinoma
Pancreatic cancer

[182]
[183]
[184]
[171, 173]
[170]
[185]
[186]
[187, 188]

induced NR4A1 nuclear export and interaction with Bcl-2 at the ER. This interaction led
to Ca2+ release from the ER and subsequent ER stress, resulting in apoptosis via ERmediated caspase-4 activation and ultimately activation of caspase-9 [186].
This apoptotic function of NR4A1 is currently being exploited for its therapeutic
potential in cancer. One class of compounds called methylene-substituted
diindolylmethanes (C-DIMs) looks especially promising as one group in particular has
been studying the utilization of C-DIMs in treating cancer via NR4A1-mediated
apoptosis [67]. C-DIMs are small lipophilic molecules synthetically derived from
cruciferous vegetables and have been found to inhibit cell and tumor growth in many
types of cancers both in vitro and in vivo [65, 170]. One C-DIM in particular, DIM-CpPhOCH3, induces apoptosis in several cancer types, and knockdown of NR4A1 inhibits
this effect in pancreatic, colon, and bladder cancer cells [187, 188]. Several pro-apoptotic
genes including TRAIL, FasL, and p21 were also induced, whereas NR4A1 knockdown
abrogated this effect [67]. Interestingly, NR4A1 was not exported from the nucleus and
did not translocate to the mitochondria during C-DIM-induced apoptosis, suggesting
NR4A1 mediates apoptosis via transcriptional activation of these pro-apoptotic genes
(Figure 1-2) [67].
On the other hand, the C-DIM analog DIM-C-pPhOH does not activate NR4A1.
Instead, it induces apoptosis by preventing NR4A1 from transcriptionally activating antiapoptotic genes such as survivin [67, 187]. Thus, C-DIMs exhibit anti-tumor properties
by acting as both activators and deactivators of NR4A1 and take advantage of the
differential activation of target genes dependent on the specific stimuli [67]. It is also
possible to synthesize NR4A1 mimics. For example, one group has created a nanopeptide
called NuBCP-9 (NR4A1-derived Bcl-2-converting peptide with 9 amino acids), which is
capable of inducing apoptosis in cancer models in vitro and in vivo by replicating the
action of NR4A1 and converting Bcl-2 to a pro-apoptotic molecule [189]. This NR4A1
mimic would be beneficial in the treatment of breast cancer since this cancer type has
higher Bcl-2 expression [172]. Furthermore, the anticancer drug paclitaxel was found to
mimic the effects of NR4A1 on Bcl-2 [190]. In all, many anti-tumorigenic compounds
can induce NR4A1-mediated apoptosis through various mechanisms including the
induction of NR4A1 expression and subsequent mitochondrial or ER targeting (CD437
and TPA), direct binding of compounds (Csn-B) with NR4A1 to activate apoptosis via
genomic and non-genomic functions, and either activating or deactivating NR4A1
transcriptional activity (C-DIMs).
MicroRNAs
Discovery and nomenclature
Discovery. The first miRNA discovered was lin-4 in Caenorhabditis elegans (C.
elegans) in 1993 [191]. Seven years passed before the second miRNA (let-7) was
identified in 2000, also in C. elegans [192, 193]. Initially, it was thought that miRNAs
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were specific to C. elegans until additional miRNAs were discovered in several other
organisms, including humans [194, 195]. To catalog of all the miRNAs identified, a
database called miRBase was created, with the most recent update released in 2014
(miRBase 21). This miRNA registry now contains 28,645 hairpin precursor miRNAs,
which represents 35,828 mature miRNAs across 223 species (miRBase 21). Of these
miRNAs, 1,881 precursors and 2,588 mature miRNAs belong to humans.
Nomenclature. For every miRNA identified, each is assigned a number
corresponding to the order in which it was discovered. To specify the organism that the
miRNA pertains to, three letters are added before the ‘miR’, such as hsa-miR-124 for
Homo sapiens and mmu-miR-124 for Mus musculus. To denote the mature form of the
miRNA, the ‘r’ is capitalized (miR-124), whereas a lower case ‘r’ (mir-124) indicates
both the gene and precursor forms. When mature miRNAs have identical sequences but
are processed from different precursor miRNAs, they are differentiated by adding a
number to the end of their name, such as miR-124-1 and miR-124-2. Conversely, mature
miRNA sequences that differ by one or two nucleotides are denoted by a letter, such as
miR-34a and miR-34b. In addition, miRNAs are processed from precursor miRNAs into
two complementary mature miRNAs where one is on the 3ʹ strand and the other resides
on the 5ʹ strand. These can be denoted by adding ‘3p’ or ‘5p’, such as miR-124-3p and
miR-124-5p. One version may be predominantly expressed over the other, and when the
dominant version is known, it keeps the common name (miR-124), whereas the less
dominant one is indicated with an asterisk (miR-124*) [196-199].
Biogenesis and function
miRNAs are non-coding RNAs consisting of 18 to 23 nucleotides that regulate
gene expression by binding to the 3ʹ untranslated region (3ʹUTR) of their target gene and
degrading the mRNA, thereby preventing its translation into protein [200, 201]. About
half of all miRNAs reside in non-protein coding genes, while the other half are usually
within the introns of protein coding transcripts [202]. RNA polymerase II transcribes
them into long primary miRNAs (pri-miRNA) that resemble a stem-loop structure, which
are then cleaved by the enzyme Drosha before becoming precursor miRNA (pre-miRNA)
[203]. These pre-miRNAs are then exported into the cytoplasm via exportin-5 in a
RanGTP-dependent fashion where they are further cleaved by Dicer into mature
miRNAs, as shown in Figure 1-3 [204-206]. During the final stage of biogenesis, the
mature miRNAs consist of two complementary strands that are separated with the more
stable passenger strand being degraded and the unstable guide strand being incorporated
into the RNAi induced silencing complex (RISC) [195, 207, 208]. This complex is then
able to bind the 3ʹUTR of its target mRNA in the seed region, which consists of 6 to 8
complementary nucleotides. Although the 3ʹUTR is the main target site, miRNAs may
also bind the 5ʹUTR as well as the coding sequence [209, 210].
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Figure 1-3. miRNA biogenesis and function.
miRNAs are transcribed by RNA polymerase II (Pol II) into either polycistronic or
monocistronic pri-miRNA, which are cleaved by Drosha into pre-miRNA. Exportin-5
mediates the translocation of pre-miRNA into the cytoplasm where it is cleaved by Dicer
into mature miRNA. A single strand of the mature miRNA is incorporated into the RISC
complex, which can then bind to the 3’UTR of target genes to mediate gene suppression.
This can lead to inhibition of NR4A oncogenic functions such as proliferation, survival,
chemoresistance, and migration.
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Therapeutic potential
miRNAs are important regulators of almost every cellular process and are
estimated to regulate 60% of the human genome [211]. They are able to form intricate
networks wherein a single miRNA can target hundreds of genes, while a single gene may
be targeted by numerous miRNAs. This complex regulation has the potential to have
profound effects on biological processes. For example, miRNAs have been shown to play
important roles in cancer where they can act as tumor suppressors by targeting oncogenes
or as oncomiRs by targeting tumor suppressors [212, 213]. Furthermore, many cancers
exhibit aberrant miRNA expression where the tumor suppressor-like miRNAs are
downregulated, most likely due to hypermethylation of the promoter [214].
In addition to miRNAs acting as biomarkers, they have also seen increased
potential for use as therapeutic agents such as miRNA replacement therapy using miRNA
mimics [215]. For instance, the miR-34 family harbors strong inhibitory effects on tumor
growth in a variety of cancers. It exerts these effects through a number of mechanisms
including the direct suppression of mitogenic genes (cyclin E2, E2F3, and CDK4) as well
as the anti-apoptotic gene SIRT1, allowing for increased expression of the apoptotic
genes p53, p21, and PUMA [216]. In addition, p53 induces miR-34 expression, resulting
in a positive feedback loop [217, 218]. A cancer therapy utilizing the power of miR-34 is
currently being tested where a miR-34 mimic is encapsulated in a liposome to allow for
more targeted delivery in a range of cancers and is currently being tested in phase I
clinical trials. This is the first miRNA to enter clinical trials, and the results thus far
appear promising [219]. Many other tumor suppressor-like miRNAs exist with similar
effects to miR-34, suggesting the potential for further exploration of miRNA replacement
therapy if the miR-34 mimic proves successful.
On the other hand, miRNAs may play an oncogenic role such as the miR-17-92
cluster promoting tumorigenesis in a wide range of cancers [220]. In addition to cancer,
miRNAs can have important functions in metabolic disorders, autoimmune diseases,
genetic diseases, and infectious diseases [195]. Of importance, the viral replication of
hepatitis C virus (HCV) was found to be dependent on miR-122 [221]. In order to block
miR-122 function, a drug was developed (SPC3649) to effectively bind the miRNA in a
locked nucleic acid fashion. After successful experimentation in chimpanzees, the drug is
currently being tested in phase II clinical trials in humans [222]. If successful, this will be
the first miRNA-based therapy for HCV [195].
Hypothesis and Specific Aims
Studies have shown that NR4A1 is upregulated in many solid tumors, and this
overexpression can lead to increased cell proliferation in cancer cell lines, indicating an
oncogenic role for this nuclear receptor. Our overall hypothesis is that miRNAs can
regulate the expression and downstream function of NR4A1, as depicted in Figure 1-3.
We theorize that one of the causes for upregulation of NR4A1 in cancer is due to
downregulation of tumor suppressor-like miRNA regulators of NR4A1.
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In addition to this first project, we decided to explore the potential function of
NR4A1 during the differentiation of skeletal muscle. Previous studies found that NR4A1
expression increases during skeletal muscle differentiation. Thus, we hypothesize that
NR4A1 is playing a pro-myogenic role during this process. To investigate these
hypotheses, we proposed the following aims:
1. Elucidate the miRNAs that are directly regulating NR4A1 and their effects on the
proliferative function of NR4A1 in pediatric cancer cell lines.
2. Determine the importance of NR4A1 in skeletal muscle differentiation.
Significance of Study
NR4A1 has been mainly studied in adult cancers, with little research on its role in
pediatric cancers. Although we propose to focus on pediatric cancer types, this novel
study of the interaction between miRNAs and NR4A1 could have therapeutic potential in
both adult and pediatric cancers. NR4A1 is an ideal candidate for a therapeutic target and
a potential biomarker in cancer. On the other hand, miRNAs can act as tumor suppressors
and are useful as prognostic markers as well as miRNA mimic therapy to treat a variety
of cancers.
The discovery of miRNAs that target NR4A1 will add a new aspect to NR4A1
regulation. This study could demonstrate clinical translation through the use of in vivo
models in which miRNAs are used as therapy for the pediatric tumors in which NR4A1 is
aberrantly amplified. The majority of published research on NR4A1 as a therapeutic
target involves utilizing agonists to induce NR4A1-mediated apoptosis, but none have
delved into using miRNAs to influence NR4A1 expression and genomic actions.
In addition, our initial studies show that differentiation of skeletal muscle cells is
severely delayed upon knockdown of NR4A1. This data supports previous studies
showing the importance of NR4A1 in the muscle mass of mice. This information could
be useful in terms of cancer therapy since malignancies such as rhabdomyosarcoma
(RMS) form as a result of cells failing to differentiate. Furthermore, muscle-related
diseases can arise such as muscular dystrophy, a disease that is prevalent in younger
populations and is characterized by loss of muscle mass and progressive weakness.
Determining the role of NR4A1 during skeletal muscle differentiation may help
understand the formation of RMS as well as diseases related to muscle.
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CHAPTER 2.

THE REGULATORY EFFECTS OF MICRORNAS ON NR4A1 IN
CANCER
Introduction

NR4A1, a member of the NR4A family of nuclear receptors, is known for its
oncogenic effects in cancer cells. These effects are heavily dependent on its role as a
transcription factor to promote expression of genes leading to cell proliferation and
survival. The expression and function of NR4A1 are regulated by post-translational
modifications and protein-protein interactions, as well as transcriptional regulation by
other transcription factors. NR4A1 is aberrantly expressed in many cancers, and one way
to therapeutically modulate its expression is through microRNA (miRNA) replacement
therapy. This chapter will explore the ways in which miRNAs may be affecting NR4A1
expression and function in the context of cancer. The role of NR4A1 in cancer will first
be discussed, followed by the many different ways it may be regulated by miRNAs. Both
direct and indirect effects will be detailed since there are not many miRNAs shown to
target NR4A1 directly. miRNAs may be targeting NR4A1 indirectly by preventing the
expression of genes that would normally interact and regulate NR4A1 via transcriptional
regulation, post-translational modifications, and protein-protein interactions. These
regulatory networks will be related back to cancer and hypothetical situations will be
discussed on how they may affect tumor formation and progression. It is important to
understand these networks in order to determine the best possible way for treating
cancers in which NR4A1 is aberrantly expressed and plays oncogenic roles.
NR4A1 in Cancer
In many adult cancers, NR4A1 is overexpressed and appears to play a
proliferative role. Bladder [223, 224], breast [187, 225-228], colon [180, 188, 228-231],
liver [176, 231, 232], pancreatic [233, 234], prostate [235], ovarian [228, 236], and lung
[167, 228, 237, 238] cancer all display increased NR4A1 compared to their normal
counterparts, with melanoma [228] expressing the highest levels of NR4A1. The
transactivation and DNA-binding domains of NR4A1 appear to be the culprit for its
proliferative function in these cancers. Through transcriptional upregulation of genes
involved in cell cycle progression and inhibition of apoptosis, NR4A1 can thereby exert
its mitogenic effects. For example in melanoma and lung cancer, NR4A1 mediates cell
cycle progression and proliferation as well as angiogenesis, which was dependent on its
transactivation and DNA binding ability [167, 239]. Furthermore, knockdown studies of
NR4A1 in many cancer cell lines resulted in decreased cell growth and angiogenesis and
increased apoptosis, providing further evidence for the role of NR4A1 as an oncogenic
factor [67]. On the other hand, NR4A1 is downregulated in acute myeloid leukemia
(AML), and Nr4a1/Nr4a3 knockout mice quickly develop AML, leading to the suspicion
that NR4A1 is playing a tumor suppressive role in this blood cancer [156]. This seems to
contradict its role in solid tumors, but it is more understandable after realizing that
NR4A1 possesses the ability to exert opposing roles in different tissues and cell types.
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NR4A1 can also wield its effects by other means, such as interacting with proteins from a
multitude of signaling pathways, as well as phosphorylation by kinases to either promote
or inhibit its translocation to the cytoplasm. As discussed below, miRNAs also factor into
this regulation of NR4A1 activity by both direct and indirect effects, thereby affecting
cancer progression in a myriad of ways.
miRNAs That Directly Target NR4A1
Currently there is a shortage of miRNAs that have been proven to target NR4A1.
According to miRTarBase there are no miRNAs that have been validated to target NR4A1
using strong evidence consisting of reporter assays, western blots, and qPCR. There are a
total of 6 miRNAs shown to target NR4A1 using less strong evidence such as microarrays
and next-generation sequencing (NGS). For example, one study used a microarray and
found that HeLa cells transfected with miR-124 had decreased NR4A1 mRNA [240].
Another study also used a microarray and showed that rno-miR-290 targets Nr4a1 in the
rat brain [241]. However, there is one recent study that does validate the targeting of
NR4A1 by miR-124, miR-15a, and miR-224 through the use of reporter assays, western
blot, and qPCR. This study also found that miR-124 can suppress the transcriptional
activity of NR4A1 in Daoy medulloblastoma cells. When miR-124 was exogenously
expressed in these cells, proliferation and viability were significantly decreased [242].
Although miR-124 is predicted to target many other genes, it is possible that it is causing
these anti-tumor effects through the suppression of NR4A1. miR-124 is an interesting
miRNA because it is the most abundant miRNA in the brain with a role in neuronal
differentiation. It is a tumor suppressor in many cancer types, several of which express
aberrantly low levels of this miRNA. Since NR4A1 is commonly upregulated in cancer,
it is easy to see how this aberrant upregulation could be due to the downregulation of
miRNAs that target it such as miR-124.
miRNAs That Indirectly Affect NR4A1 Expression and Function
Proteins that modulate NR4A1 mRNA expression
There are several ways in which miRNAs may indirectly affect NR4A1
expression and function. One way is by targeting proteins that modulate NR4A1 mRNA
expression. For example, the histone acetyltransferase p300 can acetylate NR4A1, thereby
enhancing its expression in HepG2 and HeLa cells [243]. In addition, the transcription
factor AP-1 was shown to bind the promoter of NR4A1 and induce its expression in colon
cancer cells after exogenous β-catenin expression [230]. β-catenin was also found to
increase NR4A1 transcription through hypoxia-inducible factor 1-alpha (HIF-1α) in colon
cancer cells in response to hypoxic conditions [244]. β-catenin is aberrantly activated in
90% of colon tumors and acts as an oncogene in this cancer [230], therefore it would
appear that β-catenin is exerting its proliferative effects partly through its induction of
NR4A1. HIF-1α was also found to bind to the promoter of NR4A1 and promote its
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expression in several cancer cell types including renal cell carcinoma, neuroblastoma
[245], hepatocellular carcinoma (HCC), cervical cancer, and breast cancer [246]. EP300
(encodes p300), FOS and JUN (comprises AP-1), CTNNB1 (encodes β-catenin), and
HIF1A are targeted and repressed by many miRNAs as listed in Table 2-1. Upon
repression of these genes by miRNAs, NR4A1 expression would also theoretically
decrease. On the other hand, HDAC1 is able to repress NR4A1 in HepG2 and HeLa cells
[243]. Therefore any miRNAs that target and suppress HDAC1 would result in enhanced
NR4A1 expression.
Proteins that directly bind NR4A1
RXR. Another way miRNAs may indirectly affect NR4A1 is by targeting binding
partners of NR4A1 that in turn affect its localization and function, as depicted in
Figure 2-1. One of the most complex interactions may be with the retinoid X receptor
(RXR). Depending on experimental conditions and external stimuli, RXR may
heterodimerize with NR4A1 and either bind to DNA to modulate gene expression or
localize to the mitochondria to induce apoptosis. When prostate and lung cancer cells
were treated with apoptosis-inducing agents 3-Cl-AHPC and TPA (12-O-tetradecanoyl13-phorbol acetate), RXRα formed a heterodimer with NR4A1 and translocated to the
mitochondria to induce apoptosis [162]. However, translocation of this heterodimer and
subsequent apoptosis were inhibited by the RXR ligand 9-cis-retinoic acid (9-cis-RA)
[162]. This RXR ligand along with RXR-selective retinoids, SR11246 and SR11345,
strongly promote RXR/NR4A1 heterodimer binding to the retinoic acid response element
βRARE [91, 162, 247, 248], although NR4A1 can also increase RA response element
transcription independent of retinoic acid [247]. Contrary to this finding, one group found
that 9-cis-RA actually enhanced RXR/NR4A1 dimerization and translocation to the
mitochondria, along with subsequent apoptosis [249]. This group also found that NR4A1
binding to RXR could suppress p300-mediated RXR acetylation, thereby decreasing the
transcriptional and mitogenic activity of RXR [249]. It appears that the interactions and
effects of NR4A1/RXR heterodimerization are dependent on many factors, and that
seemingly contradictory findings may be due to differences in cell types among other
factors. There are only a few miRNAs that directly target RXRA, including miR-128 and
miR-574 [250, 251]. Therefore it is possible that expression of these miRNAs result in
the opposite effects described here.
COUP-TF. In addition to RXR, the COUP-TF (chicken ovalbumin upstream
promoter-transcription factor) orphan receptors can also bind with NR4A1 and have
varying effects. In the absence of ligand, COUP-TFs bind RAREs and inhibit their
transcription, leading to decreased RARB and increased cell growth, at least in breast and
lung cancer. However in the presence of RA, COUP-TF has no effect on βRARE
transcription and therefore enhances the anti-tumor effects of RA, leading to the
conclusion that COUP-TF sensitizes cancer cells to RA. In lung cancer cells, NR4A1
heterodimerizes with COUP-TF and prevents binding to the βRARE, thereby
desensitizing the cells to RA. On the other hand, COUP-TF can prevent NR4A1/RXR
heterodimer binding to the βRARE via protein-protein interaction. Furthermore, COUP-
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Table 2-1.
Functional
relationship to
NR4A
Modulates
Nur77 mRNA
expression

Binds Nur77
protein

Effects of Nur77 regulatory networks on cancer and potential implications by miRNAs.
Gene
(common
name)
EP300
(p300)

Effect on NR4A/functional
consequence

Oncogenic
effect?

Cancer type/disease

miRNAs

Promotes expression via acetylation

Yes

Liver, cervical

20a, 26a, 106b~25, 132, 150,
574

[252-257]

Fos/Jun
(AP-1)
HIF1A
(HIF-1α)

Promotes expression by directly
binding to promoter
Promotes expression by directly
binding to promoter

Yes

Colon

101, 181b, 155

[258-263]

Yes

Neuroblastoma,
cervical, breast, liver

[264-279]

CTNNB1
(β-catenin)
HDAC1

Promotes expression via activation of
AP-1
Suppresses expression

Yes

Colon

No

Liver, cervical

17~92, 18a, 20b, 31, 93, 138,
155, 199ab, 206, 210, 335,
338, 519c
34, 185, 200abc, 203, 214,
434, 680, 690
34a, 449ab, 874

RXRA
(RXRα)

RXR/Nur77 heterodimer either
activates transcription or translocates
to mitochondria to induce apoptosis
Binds and prevents Nur77 from
binding to RXR, thereby resensitizing
cells to RA
Inhibits mitochondrial targeting

Yes and
No

Lung, pancreatic

128, 574

[250, 251]

Yes and
No

Lung

194, 302a

[295, 296]

Yes

Liver

None

Nur77 prevents Ku80-mediated DNA
repair
Nur77 blocks p53 transcriptional
activity/promotes p53-mediated
apoptosis
Nur77 prevents LKB1 from
suppressing mTOR
Pin1 promotes Nur77 transcriptional
activity

No

Liver

31, 526b

[297, 298]

Yes and
No

Lung, liver, bone

25, 30d, 125, 150, 375, 504,
1285

[299-305]

Yes

Cervical

155

[306]

Yes

Cervical

140, 200bc, 296

[307-309]

NR2F2
(COUP-TF)
CHD1L
XRCC5
(Ku80)
TP53 (p53)

STK11
(LKB1)
PIN1 (Pin1)
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miRNA
references

[280-286]
[287-294]

Table 2-1.
Functional
relationship to
NR4A

Continued.
Gene
(common
name)
EP300
(p300)
CTNNB1
(β-catenin)
NDRG1

Oncogenic
effect?

Nur77 either inhibits p300 or forms
complex to promote transcription
Nur77 inhibits β-catenin function

miRNA
references

Cancer type/disease

miRNAs

Yes and
No
No

Cervical, breast, lung

[252-257]

Competitively binds Nur77 and
prevents it from inducing β-catenin
degradation
Nur77 inhibits the pVHL-mediated
ubiquitination of HIF-1α
SHP blocks Nur77 from
transcriptionally mediating cell death
upon treatment with an apoptosisinducer
Nur77 prevents PKC from activating
AP-1 and NF-kB
Inhibits Nur77 transcriptional activity

Yes

Liver

20a, 26a, 106b~25, 132, 150,
574
34, 185, 200abc, 203, 214,
434, 680, 690
182, 769

Yes

21

[312]

Yes

Neuroblastoma, renal
cell carcinoma
Liver

141, 378g, 4649

[313-315]

No

Acute T cell leukemia

24-2

[316]

No

osteosarcoma

None

Yes

Gastric

100, 105, 133b, 143, 149, 342

[317-322]

JNK

Nur77 mitochondrial targeting is
blocked by Akt
JNK induces Nur77 mitochondrial
targeting and inhibits its transcriptional
activity

No

92a

[323]

PRKDC
(DNAPKcs)

Nur77 induces apoptosis upon ionizing
radiation treatment, which is dependent
on its phosphorylation by DNA-PKcs

No

Lung, prostate, breast,
glioma, ovarian, oral
squamous cell
carcinoma
Liver

101

[324]

VHL
(pVHL)
NR0B2
(SHP)

PRKCA
(PKC)
PML
Phosphorylates
Nur77

Effect on NR4A/functional
consequence

AKT1 (Akt)
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Colon

[280-286]
[310, 311]

Table 2-1.

Continued.

Functional
relationship to
NR4A

Transcriptional
target of Nur77

Gene
(common
name)
GSK3B
(GSK-3β)
CCND2
(cyclin D2)

TXNDC5
BIRC5
(survivin)
E2F1

CDK4
BRE
RBBP8
MAP4K5
STAT5A

Effect on NR4A/functional
consequence

Oncogenic
effect?

Cancer type/disease

miRNAs

miRNA
references

Nur77 is blocked from inhibiting Bcatenin transcriptional activity upon
phosphorylation by GSK-3B
Promotes proliferation via cyclin D2

Yes

Colon

26a, 346

[325, 326]

Yes

Cervical

[327-350]

Promotes lower stress levels and
therefore increased survival
Promotes survival

Yes

Pancreatic

1, let-7a, 15b, 16, 26a, 29abc,
30c, 98, 124a, 145, 182, 195,
198, 204, 206, 302b, 340, 375,
497, 610
200b

Yes

Pancreatic

[352-361]

TPA induces Nur77, resulting in
increased E2F1 and apoptosis; Pin1
promotes Nur77 to transcriptionally
activate E2F1, resulting in increased
proliferation
Nur77 activates CDK4 following
induction by bile acids
Nur77 activates BRE following
induction by bile acids
Nur77 activates RBBP8 following
induction by bile acids
Nur77 activates MAP4K5 following
induction by bile acids
Nur77 activates STAT5A following
induction by bile acids

Yes and
No

Prostate, cervical

16, 195~497, 203, 218, 542,
708
106a, 136, 149, 205, 223, 320,
326, 329, 330, 331, 342, 362,
493, 603

Yes

Liver, colon

[341, 375387]

Yes

Liver, colon

1, 34a, 124, 188, 195, 206,
486, 506, 613
None

Yes

Liver, colon

19ab, 335

[388, 389]

Yes

Liver, colon

None

Yes

Liver, colon

141, 222, 223, 1469
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[351]

[321, 362374]

[390-393]

Table 2-1.
Functional
relationship to
NR4A

Continued.
Gene
(common
name)
BID
POMC
CITED1
DACT1
MYC

Effect on NR4A/functional
consequence

Oncogenic
effect?

Cancer type/disease

miRNAs

Nur77 activates BID following
induction by bile acids
Nur77 promotes POMC expression

No

Liver, colon

None

Yes

Cushing's disease

None

Nur77 represses CITED1, allowing
Wnt activation
Nur77 represses DACT1, allowing
Wnt activation
Nur77 represses MYC

Yes

Melanoma

None

Yes

Melanoma

None

No

Acute myeloid
leukemia

let-7g, 24, 34abc, 126, 135b,
145, 185, 320b, 487b, 494,
744

29

miRNA
references

[394-408]

Figure 2-1. NR4A1 mediates cell proliferation and survival in addition to cell
death.
The top panel depicts genes that transcriptionally activate NR4A1, leading to NR4A1
interactions that ultimately promote cell proliferation and survival. In contrast, the bottom
panel details the actions of NR4A1 in response to apoptotic stimuli, resulting in
translocation of NR4A1 to the mitochondria and induction of apoptosis.
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TF expression was positively correlated with RA sensitivity, while NR4A1 expression
was associated with retinoid resistance in lung cancer cells. This suggests NR4A1 is
responsible for RA resistance, leading to enhanced cell proliferation [247]. miRNAs
capable of directly binding and suppressing NR2F2 (encodes COUP-TF) include miR194 and miR-302a. COUP-TF suppresses osteoblastic differentiation, and overexpression
of miR-194 and miR-302a was found to rescue this effect [295, 296]. This leads us to
speculate that expression of these miRNAs would result in the desensitization of cancer
cells to RA treatment mediated by NR4A1.
CHD1L. The next gene that physically interacts with NR4A1 is CHD1L. This
protein acts as an oncogene in hepatocellular carcinoma and can bind with NR4A1 to
prevent its translocation to the mitochondria and subsequent apoptosis upon treatment
with staurosporine [409]. Unfortunately, there are no miRNAs that have been validated to
target CHD1L. However, CHD1L interacts with Ku70 and DNA-dependent protein
kinase, catalytic subunit (DNA-PKcs) to enhance chromatin remodeling and DNA repair
[410, 411], although its elevated levels in cancer surprisingly lead to increased DNA
damage. The DNA-PK complex is essential for mediating double-strand break repair and
comprises DNA-PKcs and Ku70/Ku80. Since NR4A1 is known to interact with Ku80 to
suppress DNA repair [232] and has also been shown to bind CHD1L, it is possible that
NR4A1 inhibits DNA repair via protein-protein interactions with Ku80 and/or CHD1L.
There are presently two miRNAs shown to target XRCC5 (encodes Ku80), including
miR-31 and miR-526b [297, 298]. Therefore expression of these miRNAs may lead to
increased DNA damage, which would most likely lead to cell death.
p53. One of the more significant binding partners of NR4A1 is the tumor
suppressor p53, and similar to some of its previously discussed binding partners, this
interaction can lead to contradictory outcomes. NR4A1 can play an oncogenic role by
binding to p53 and preventing p300 acetylation of p53, resulting in suppressed p53
transcriptional activity [412]. In addition, NR4A1 can circuitously promote oncogenic
mTOR signaling by inhibiting p53-mediated transcription of sestrin-2, an activator of
AMPK, which is an inhibitor of mTOR [238, 413]. However in the presence of DNAPKcs, NR4A1 is phosphorylated by DNA-PKcs and becomes an activator of p53
transcriptional activity via phosphorylation of p53 by DNA-PKcs. In addition to
increasing p53 transactivation, NR4A1 heterodimerization with p53 can enhance p53mediated apoptosis as well as p53 protein stability by blocking ubiquitination and
subsequent degradation of p53 by MDM2 [412]. As listed in Table 2-1, many miRNAs
have been found to target TP53. Since p53 is a tumor suppressor, this would imply that
any miRNA that targets it is likely an oncomiR.
LKB1. Another way in which NR4A1 promotes mTOR signaling is by inhibiting
LKB1. NR4A1 binds LKB1 and blocks it from activating AMPK, thereby preventing
AMPK from inhibiting mTOR. This leads to enhanced mTOR signaling and therefore
increased proliferation, survival, and angiogenesis [414]. Interestingly, miR-155 was
found to promote proliferation of cervical cancer cells by targeting STK11 (encodes
LKB1), therefore acting as an oncomiR [306].
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Pin1 and p300. Additional proteins that interact with NR4A1 include p300 and
Pin1. NR4A1 isomerization and increased protein stability is mediated by Pin1 and
enhances recruitment of p300, thereby increasing the transcriptional activity of NR4A1
and its downstream proliferative effects [415]. NR4A1 can also form a complex with
p300 and Sp1 to promote expression of proliferative and prosurvival genes such as
survivin in lung cancer cells [238]. On the other hand, NR4A1 can directly interact with
p300 and block its ability to acetylate transcription factors, thereby repressing their
transcriptional activity and resulting in decreased proliferation in breast cancer cells
[416]. Five miRNAs target EP300, including miR-20a [252], miR-132 [256], miR-150
[254], and miR-574 [253], as well as the miR-106b~25 cluster [255]. In addition, miR200b [307], miR-200c [308], and miR-296 [309] were found to target PIN1. All of these
miRNAs, with the exception of miR-20a and the miR-106b~25 cluster, play mostly
tumor suppressive roles. Therefore it would make sense that expression of these miRNAs
would have a negative impact on NR4A1 function via targeting of EP300 and PIN1.
β-catenin. The proto-oncogene β-catenin is often mutated in cancer and interacts
with transcription factors to promote expression of mitogenic genes. NR4A1 acts as a
negative regulator of β-catenin function either by inducing its degradation in the
cytoplasm [417] or by blocking its interaction with the transcription factor TCF4 and
promoting recruitment of corepressors, thereby suppressing its transcriptional activity in
colon cancer [418]. In contrast, NR4A1 was found to activate and stabilize β-catenin
protein and prevent its degradation under hypoxic conditions via NR4A1-mediated
activation of the Akt pathway. As mentioned, β-catenin can promote NR4A1 expression,
thereby forming a positive feedback loop that promotes the proliferation of colon cancer
cells [244]. CTNNB1 (encodes β-catenin) is targeted by miR-34 [280, 419], miR-200a
[282-284], and miR-214 [285, 286], all of which act as tumor suppressors in several
cancer types. Five other miRNAs have also been shown to directly target CTNNB1 [281],
and expression of these miRNAs may either relieve NR4A1 of its inhibitory effect on βcatenin, or suppress the NR4A1-mediated activation of β-catenin induced by hypoxia.
NDRG1. N-myc downstream regulated gene 1 (NDRG1) acts as an oncogene in
hepatocellular carcinoma by promoting β-catenin accumulation. It does so by
competitively binding with glycogen synthase kinase-3β (GSK-3β) and NR4A1
individually, thus preventing β-catenin degradation by GSK-3β and NR4A1. This
inhibitory mechanism by NDRG1 results in upregulation of downstream oncogenic genes
[420]. miR-182 acts as an oncomiR in prostate cancer [310] while miR-769 [311] plays a
tumor suppressive role in breast cancer, both of which mediate their effects by directly
targeting NDRG1. However in HCC, expression of these miRNAs would presumably
result in increased β-catenin degradation via NR4A1 and GSK-3β, thus leading to antiproliferative effects.
SHP. Small heterodimer partner (SHP) commonly inhibits nuclear receptor
function via physical interaction and was found to bind and suppress NR4A1
transcriptional activity. When HCC cells were treated with an inducer of apoptosis, SHP
prevented NR4A1 from transcriptionally mediating cell death [421]. There are three
miRNAs that target NR0B2 (encodes SHP), including miR-141 [313], miR-378g [314],
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and miR-4649 [315], expression of which would theoretically lead to enhanced apoptosis
mediated by NR4A1.
PKC. As mentioned briefly, NR4A1 appears to be a tumor suppressor in
leukemia. One way NR4A1 may mediate this effect is by interacting with and inhibiting
protein kinase C (PKC). In Jurkat leukemic T cells, the LBD of NR4A1 binds PKC and
prevents it from activating AP-1 and NF-kB [422]. The activation of NF-kB by PKC can
lead to induction of anti-apoptotic genes, and since NR4A1 is known to induce apoptosis
in T cells, its inhibition on PKC may be necessary in order for apoptosis to occur. miR24-2 is the only miRNA that has been shown to directly target PRKCA (PKC) and was
found to decrease cell survival in breast cancer cells via PKC inhibition [316].
PML. Another way NR4A1 is involved in leukemia is through its interaction with
the promyelocytic leukemia gene, PML [423]. Patients with acute promyelocytic
leukemia commonly have a chromosomal translocation that results in fusion genes
encoding PML-RARα and RARα-PML [424]. PML is well known for its ability to inhibit
cell proliferation and to act as a tumor suppressor in vivo [425-429]. PML was also found
to directly interact with NR4A1 in its DBD domain and prevent its transcriptional activity
in osteosarcoma cells [423]. Thus far there have not been any miRNAs found to target
PML, but hypothetically any miRNA that suppresses PML would result in increased
transcriptional activity by NR4A1.
VHL. Lastly, the tumor suppressor von Hippel-Lindau (pVHL) is an E3 ubiquitin
ligase that forms a multimeric complex to degrade proteins and has been implicated in
several diseases as a result of mutations in pVHL. One of its target proteins is HIF-1α,
which gets ubiquitinated upon binding with pVHL and subsequently degraded. However,
NR4A1 is able to bind pVHL and prevent this HIF-1α ubiquination [430]. As mentioned,
HIF-1α can transcriptionally promote expression of NR4A1, which was shown in VHLdeficient renal cell carcinoma [245], as well as other cancer cell lines [246]. Since both
NR4A1 and HIF-1α are known to enhance expression of oncogenic genes via their
transactivation functions, it is understandable that they would have a synergistic effect.
VHL is targeted by miR-21 [312], expression of which would result in increased HIF-1α
protein stability and transcriptional activity.
Proteins that phosphorylate NR4A1
Akt. Furthermore, miRNAs may target protein kinases that are responsible for the
copious amounts of phosphorylation endured by NR4A1 on its N-terminus [86]. Some of
these kinases positively regulate NR4A1 and mediate either its cell death or cell
proliferation effects, while other kinases block these functions. Most studies that involve
NR4A1-mediated apoptosis use external stimuli to force these effects. For example,
gastric cancer cells treated with TPA experience cell death due to the translocation of
NR4A1 to the mitochondria and ensuing induction of apoptosis. However,
phosphorylation of NR4A1 by Akt, a serine/threonine kinase, blocks the mitochondrial
targeting of NR4A1 along with its interaction with Bcl-2 [431]. Other studies have also
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verified this negative effect of Akt on NR4A1-induced apoptosis, as well as an inhibitory
effect on NR4A1 transcriptional activity [121, 432]. Furthermore, CHD1L indirectly
activates Akt, leading to inhibition of cell death [433]. As discussed, CHD1L is also able
to block apoptosis by directly binding NR4A1; therefore the activation of Akt is an
additional mechanism by which CHD1L can prevent cell death via inhibition of NR4A1.
miRNAs that target AKT1 would theoretically alleviate the suppression of NR4A1 by
Akt. Several of these miRNAs act as tumor suppressors, including miR-105 and miR133b, which were found to act as tumor suppressors in HCC and bladder cancer,
respectively, via inhibition of AKT1 [318, 319].
JNK. On the other hand, phosphorylation of NR4A1 by c-Jun N terminal kinase
(JNK) promotes the translocation and mitochondrial targeting of NR4A1. This NR4A1mediated apoptosis occurs in the presence of several different cytotoxic compounds.
Many of these compounds also upregulate NR4A1 expression, including 6-[3-(1adamantyl)-4-hydroxyphenyl]- 2-naphthalene carboxylic acid (AHPN). This retinoid is a
potent inducer of apoptosis in several cancer types, and addition of 3-Cl-AHPC (an
analog of AHPN) to lung, prostate, and breast cancer cells induces phosphorylation of
NR4A1 by JNK followed by its translocation to the mitochondria and subsequent
apoptosis [167, 434]. Treatment of lung cancer cells with 3-Cl-AHPC also inhibits
NR4A1 transcriptional activity [167]. In addition, apaensin, a plant-derived natural
product, induces apoptosis in lung and breast cancer cells via NR4A1, which is mediated
by JNK phosphorylation [435]. Furthermore, glioma and oral squamous cell carcinoma
treated with PCH4, a derivative of n-butylidenephthalide, induced apoptosis, which was
dependent upon the mitochondrial targeting of NR4A1 mediated by JNK [436, 437].
Interestingly, the nuclear export of NR4A1 occurs in cisplatin-sensitive ovarian cancer
cells but not in cisplatin-resistant cells. Cisplatin-induced apoptosis is dependent on the
translocation of NR4A1 mediated by JNK phosphorylation [179]. There are no known
miRNAs that target human MAPK8 (JNK), although miR-92a has been shown to target
mouse Mapk8 [323]. Expression of miR-92a would hypothetically suppress NR4A1
translocation and instead allow for cell survival and proliferation via inhibition of JNK.
DNA-PKcs. In addition to JNK, DNA-PKcs also positively regulates NR4A1.
DNA-PKcs phosphorylates NR4A1 and increases its protein levels in liver cancer cells.
As mentioned previously, this phosphorylation of NR4A1 enhances the transcriptional
activity and phosphorylation of p53 by DNA-PK. Hepatoma cells treated with ionizing
radiation (IR) leads to DNA-PKcs-mediated upregulation of NR4A1, which results in
apoptosis induced by NR4A1 [232]. miR-101 was found to sensitize glioma and lung
tumors to radiation via direct suppression of PRKDC (encodes DNA-PKcs) [324].
Paradoxically, decreased PRKDC by miR-101 should result in reduced NR4A1-mediated
apoptosis, but perhaps miR-101-mediated apoptosis is occurring via NR4A1-independent
mechanisms.
GSK-3β. As stated earlier, NR4A1 prohibits the transcriptional activity of βcatenin by disrupting the DNA binding of β-catenin and TCF4 and promotes the
recruitment of corepressors to Wnt target genes, thereby attenuating tumor growth.
However, this negative regulation by NR4A1 is prevented upon phosphorylation by
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GSK-3β, which is a phenomenon observed in most clinical colorectal cancers [418]. This
phosphorylation of NR4A1 by GSK-3β allows β-catenin to transcriptionally activate
genes involved in cell proliferation, leading to cancer progression. This may seem
contradictory to the main function of GSK-3β, which is to promote degradation of βcatenin, leading to tumor suppression. However in colorectal cancer, GSK-3β may have
evolved in the tumor microenvironment to instead support β-catenin activity via
inhibition of NR4A1. Therefore in this scenario, miRNAs that target and inhibit GSK3B
should lead to decreased tumor growth since GSK-3β can no longer prevent NR4A1mediated degradation of β-catenin. miR-26a promotes cholangiocarcinoma [325] and
miR-346 promotes osteogenic differentiation [326], both of which mediate their effects
by directly targeting GSK3B.
Target genes of NR4A1
Proliferation and survival genes. Lastly, miRNAs may attenuate the
transcriptional activity of NR4A1 by targeting and suppressing the expression of NR4A1
target genes. Transcriptional targets of NR4A1 that mediate its proliferation and survival
functions include CCND2 (cyclin D2) [415], E2F1 [415, 438], thioredoxin domain
containing 5 (TXNDC5) [439], and BIRC5 (survivin) [233, 238]. Many of these genes act
as oncogenes, for example survivin is overexpressed in many cancers including
pancreatic cancer, where it was found that NR4A1-induced survivin expression is
essential for pancreatic cancer cell growth [233, 238]. In addition to survivin, TXNDC5
is also upregulated in several cancer types and was found to promote proliferation and
migration while decreasing apoptosis in gastric cancer cells [440]. TXNDC5 is induced
by NR4A1 in pancreatic cancer cells, leading to lower stress levels that permit increased
cancer cell growth and survival [439]. Cyclin D2 and E2F1 expression induced by
NR4A1 was also found to increase cell proliferation [415], although induction of NR4A1
by TPA actually resulted in increased apoptosis via E2F1 in prostate cancer cells [438].
Numerous miRNAs have been found to directly target these genes, and expression of
these miRNAs typically results in decreased proliferation and survival (Table 2-1).
Pro-inflammatory genes. Furthermore, liver and colon cancer cells treated with
bile acids (BAs) experienced a substantial increase in NR4A1 expression, leading to the
upregulation of pro-inflammatory genes subsequently identified as NR4A1 target genes.
These include CDK4, CCND2, BRE, RBBP8, MAP4K5, and STAT5A, which most likely
mediate the increased proliferation and migration observed upon BA-induced NR4A1
overexpression [231]. Surprisingly, NR4A1 was also found to induce the proapoptotic
gene BID [231]. miRNAs that target and suppress the expression of NR4A1 target genes
would therefore attenuate the effects of NR4A1 transcriptional activity, and in this case
the miRNAs would act as tumor suppressors in liver and colon cancers (Table 2-1).
POMC. An RXR agonist, HX630, suppresses NR4A1 and its transcriptional
induction of pro-opiomelanocortin (POMC), leading to the inhibition of corticotroph
tumor growth [441]. Corticotroph tumors that secrete excessive amounts of
adrenocorticotropic hormone (ACTH) can develop into Cushing’s disease [441].
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Therefore, NR4A1-mediated induction of POMC may lead to the formation of
corticotroph tumors and downstream Cushing’s disease. miRNAs that block expression
of POMC would thus decrease the formation of corticotroph tumors and the likelihood of
Cushing’s disease. Unfortunately, no miRNAs have been verified to target POMC as of
yet.
Negative regulators of Wnt. Over 70% of melanomas have a mutation in NRAS
or BRAF, resulting in aberrant and constitutive signaling of the MAPK pathway and
downstream proliferative effects. When NR4A1 is knocked down in melanoma cells via
siRNA, antagonists of the Wnt pathway, DACT1 and CITED1, were upregulated [442].
Therefore, NR4A1 acts to transcriptionally suppress these antagonists, resulting in the
continued activation of the Wnt pathway. This further supports the role of NR4A1 as an
oncogenic factor, especially in the case of melanoma since NR4A1 has the highest
expression in this cancer compared to all other cancer types. Currently, there are no
known miRNAs that target DACT1 and CITED1, although several miRNAs are predicted
to target DACT1 in the TargetScan database. Expression of these predicted miRNAs
would theoretically support the function of NR4A1 and promote activation of the Wnt
pathway.
Myc and Bcl-2. On the other hand, NR4A1 plays a tumor suppressive role in
AML by binding to the promoter of MYC and suppressing its transcription, thereby
preventing its downstream oncogenic effects. NR4A1 was also found to decrease BCL2
expression, although it is unclear if it directly binds the promoter. Myc and Bcl-2 work
together to promote AML, therefore NR4A1-mediated suppression of BCL2 further
attenuates the oncogenic activity of Myc. Furthermore, the leukemogenicity of AML
cells was prevented by overexpression of NR4A1 in vivo [443]. There are many miRNAs
that target MYC and BCL2, and expression of these miRNAs would support the role of
NR4A1 as a tumor suppressor in AML.
Conclusions
The regulatory proteins listed in this chapter are not an exhaustive list of those
that regulate and interact with NR4A1. There are many others that target it in different
contexts, however only the proteins that have been shown to target and regulate NR4A1
in the context of cancer are discussed. A more thorough review that was recently
published includes all interacting factors of NR4A1 and its family members and explores
how these interactions affect various physiological processes [444].
In addition to the proteins discussed here, other transcription factors such as Sp1,
NF-kB, and CREB have all been shown to bind the promoter of NR4A1 to modulate its
expression [137, 445, 446]. Other binding partners also include NFAT, GATA4, SRC-2,
and c-JUN [77, 447-449]. An important binding partner of NR4A1 that mediates the
apoptotic effect of NR4A1 is Bcl-2 [123]. Additional kinases such as ERK2, ERK5,
RSK2, and p38α also phosphorylate NR4A1 [450-453]. Furthermore, NR4A1 has been
shown to bind the promoters and modulate expression of EDN1 (endothelin 1) and
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ITGB4 (integrin beta 4) [448, 454]. However, these proteins were not discussed in detail
since the experiments were performed in relatively normal cell lines. Due to the fact that
NR4A1 may play different and opposing roles depending on the cell line, it is possible
that it may also have different functions in cancer cells compared to normal cells.
Because NR4A1 appears to play an oncogenic role in cancer, this chapter discusses the
proteins that regulate NR4A1 in a malignant environment.
Many of the miRNAs discussed here correlate well with the role of NR4A1 in
cancer. Those miRNAs that are typically overexpressed in cancer and act as oncomiRs
appear to support the oncogenic functions of NR4A1 by suppressing proteins that would
otherwise attenuate the actions of NR4A1 or repress oncogenic pathways. On the other
hand, many of the miRNAs that target genes involved in NR4A1-mediated cancer
progression are known tumor suppressors. All of the miRNAs discussed and listed in
Table 2-1 have been verified to target their aforementioned targets using luciferase
assays in which the seed region was mutated to confirm direct binding, and most of them
were further verified by qPCR and western blot analysis.
It is important to note that in instances where NR4A1 mediates apoptosis in
cancer cells, it is being induced to do so upon treatment with cytotoxic compounds.
Therefore in the absence of external stimuli, it seems that the normal role of NR4A1 in
cancer is to transcriptionally promote expression of genes that are important in cell
proliferation and survival.
According to the latest research, there are numerous studies portraying NR4A1 as
an oncogenic factor. Glancing at Table 2-1, it is apparent that NR4A1 exerts is mitogenic
effects via several mechanisms. These include transcriptional regulation by other
transcription factors, protein-protein interactions, post-translational modifications such as
phosphorylation, and directly binding the promoters of target genes to drive their
expression towards a proliferative and pro-survival state. Understanding these regulatory
networks is imperative in order to develop more efficacious and personalized treatment
for cancer patients.

37

CHAPTER 3.

REGULATION OF NUCLEAR RECEPTOR NR4A1 BY
MIR-124*
Introduction

One of the ten hallmarks of cancer is uncontrolled and limitless cell growth. Cells
that have acquired the capability to proliferate indefinitely form tumors that may
metastasize and develop into cancer. In some cancers, this proliferative signaling is
controlled by certain genes that are often overexpressed and thereby constitute ideal
therapeutic targets. Some of these target genes include nuclear receptors such as the
estrogen receptor in breast cancer or the androgen receptor in prostate cancer. Another
nuclear receptor that researchers have identified as a potential therapeutic target is
NR4A1.
The nuclear receptor NR4A1 is commonly upregulated in adult cancers and has
oncogenic functions. NR4A1 is an immediate-early response gene that acts as a
transcription factor to promote proliferation and protect cells from apoptosis. Conversely,
NR4A1 can translocate to the mitochondria and induce apoptosis upon treatment with
various cytotoxic agents. The roles of NR4A1 in cancers have been investigated mostly
in adult cancers, with very few studies in childhood malignancies. NR4A1 is
downregulated in leukemia, and Nr4a1/Nr4a3 double-knockout mice quickly develop
acute myeloid leukemia before succumbing to the disease [156]; however, the expression
and function of NR4A1 have not been well studied in pediatric solid tumors. Recent data
from the Pediatric Cancer Genome Project show that NR4A1 is deleted in many
hypodiploid acute lymphoblastic leukemia tumors, whereas it is amplified in some
patients with Group 4 medulloblastoma (MB) and rhabdomyosarcoma [455].
Because NR4A1 is upregulated in cancer and may have a role in cancer
progression, it is of interest to understand the mechanism controlling its expression.
MicroRNAs (miRNAs) are responsible for inhibiting translation of their target genes by
binding to the 3ʹUTR and either degrading the mRNA or preventing it from being
translated into protein, thereby making these non-coding endogenous RNAs vital
regulators of every cellular process. Several miRNAs have been predicted to target
NR4A1; however, strong evidence showing the regulation of NR4A1 by any miRNA is
lacking. In this study, we used a luciferase reporter assay containing the 3ʹUTR of NR4A1
to screen 296 miRNAs and found that miR-124, which is the most abundant miRNA in
the brain and has a role in promoting neuronal differentiation, caused the greatest
reduction in luciferase activity. Interestingly, we discovered an inverse relationship in
Daoy medulloblastoma cells and undifferentiated granule neuron precursors in which
NR4A1 is upregulated and miR-124 is downregulated. Exogenous expression to further
--------------------*Modified with permission from PLOS ONE. Tenga, A., et al., Regulation of Nuclear
Receptor Nur77 by miR-124. PLOS ONE, 2016. 11(2): p. e0148433.
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elevate NR4A1 levels in Daoy cells increased proliferation and viability, but knocking
down NR4A1 via siRNA resulted in the opposite phenotype. Importantly, exogenous
expression of miR-124 reduced NR4A1 expression, cell viability, proliferation, and
tumor spheroid size in 3D culture. In all, we have discovered miR-124 to be
downregulated in instances of medulloblastoma in which NR4A1 is upregulated,
resulting in a proliferative state that abets cancer progression. This study provides
evidence for increasing miR-124 expression as a potential therapy for cancers with
elevated levels of NR4A1.
Methods
Cell culture
Human embryonic kidney cell line 293T (ATCC CRL-3216), human cortical
neuronal cell line HCN-2 (ATCC CRL-10742), human medulloblastoma cell lines D341
(ATCC HTB-187) and Daoy (ATCC HTB-186), and human rhabdomyosarcoma cell
lines RD (ATCC CCL-136) and SJCRh30 (ATCC CRL-2061) were obtained from ATCC
(Manassas, VA). Cells were free from contamination of mycoplasma, and passaged for
fewer than 6 months after receipt (or resuscitation). Human rhabdomyosarcoma cell line
Rh41 has been described previously [456]. 293T, HCN-2, and RD cells were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM). Rh41 and Rh30 cells were grown in
RPMI-1640 Medium, and Daoy cells were cultured in Eagle’s Minimum Essential
Medium (EMEM). UKF-NB-3 (NB3) cells, which originated from a patient with MYCNamplified stage 4 neuroblastoma [457], were cultured in Iscove’s Modified Dulbecco’s
medium (IMDM). LHCN-M2 cells (immortalized myoblasts derived from the pectoralis
major muscle [458]) were plated in gelatin-coated plates (0.1% gelatin in PBS) and
cultured in DMEM supplemented with 15% FBS, 0.02M HEPES, 0.03 µg/mL zinc
sulfate, 1.4 µg/mL vitamin B12, 0.055 µg/mL dexamethasone, 2.5ng/mL hepatocyte
growth factor (recombinant human), and 10 ng/mL basic fibroblast growth factor. All
cells were cultured at 37°C in 5% CO2, and all media (except LHCN-M2 media) were
supplemented with 10% fetal bovine serum, 1% GlutaMAX, 1% sodium pyruvate, and
1% penicillin-streptomycin (Life Technologies, Carlsbad, CA).
Reporter assay
For the miRNA screen, all miRNA constructs were obtained from an existing
library [459]. These constructs are plasmids containing the pre-miRNA sequences and
have been reconstituted in TE (10 mM Tris-HCl, pH 8.0; 0.1 mM EDTA, pH 8.0) buffer.
Each miRNA construct (0.09 μg) was first added to the well of a 96-well plate
(PerkinElmer, Waltham, MA) that were kept at 4°C until all miRNAs were plated. Next,
0.15 μg of NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTR-Luc; GeneCopoeia,
Rockville, MD) and 3 μL/μg of FuGENE 6 (Promega, Madison, WI) were mixed with 50
μL of Opti-MEM reduced-serum media (Life Technologies) and dispensed into each well
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before being overlaid with 293T cells (20,000 cells/well in 50 μL of antibiotic-free
media). NR4A1-3ʹUTR-Luc (in the pEZX-MT01 vector) contains both the firefly
luciferase gene (FLuc) fused upstream of the 3ʹUTR of NR4A1 under the control of the
SV40 promoter and the Renilla luciferase gene (RLuc) under the control of the CMV
promoter. RLuc was used as an internal transfection control. After 48 hours, the Dual-Glo
luciferase assay system (Promega) was used to detect luciferase activity according to the
manufacturer’s instructions. Raw luciferase activity was measured by using the EnVision
2101 Multilabel Plate Reader (PerkinElmer). Raw values were normalized by dividing
the FLuc values by the RLuc values and then normalized to the value of either pSIF, an
empty vector control for miRNA that contains a scrambled sequence in place of the premiRNA sequence [459], or oligo control (Cntrl) in the miR-124 inhibitor assay. The
FLuc/RLuc values for pSIF or Cntrl were set as 1. Mutations in the 3ʹUTR of NR4A1 that
disrupt the binding site of the miRNAs were made by Mutagenex (Suwanee, GA).
RNA isolation and quantitative real-time PCR
Total RNA, including miRNA, was extracted by using the Qiagen miRNeasy kit
(Qiagen, Venlo, Netherlands); the Maxwell 16 LEV simplyRNA Tissue Kit was used
with the Maxwell 16 Research Instrument (Promega) for RNA extraction only when
miRNA extraction was not needed. RNA was converted to cDNA by using the
SuperScript VILO cDNA Synthesis Kit (Life Technologies), and 2 μL of 5X Taqman
probes (Applied Biosystems) specific to each miRNA were added to enhance miRNA
detection. Target gene mRNA expression was detected by using specific Taqman probes
(20X) and quantitated via the 7900HT Fast Real-Time PCR System (Applied
Biosystems). GAPDH (4352934E) was used as an endogenous control for all gene
expression analysis, including NR4A1 (Assay ID Hs00374226_m1), E2F1 (Assay ID
Hs00153451_m1), CCND2 (Assay ID Hs00153380_m1), BIRC5 (Assay ID
Hs04194392_s1), TXNDC5 (Assay ID Hs01046709_mH), CDK4 (Assay ID
Hs01565683_g1), and STAT5A (Assay ID Hs00234181_m1). Both RNU6B (Assay ID
001093) and RNU48 (Assay ID 001006) were used as endogenous controls for miRNA
expression. RNU48 was used instead of RNU6B to analyze endogenous miRNA
expression in the cell lines because RNU48 had less variable Ct values among cell lines.
The probes used to detect miRNA levels (Applied Biosystems) were miR-124-3p (Assay
ID 001182), miR-15a-5p (Assay ID 000389), and miR-224-5p (Assay ID 002099).
Gapdh (4352932E) and Nr4a1 (Assay ID Mm01300401_m1) mouse probes were used to
detect Gapdh and Nr4a1 expression in mice. snoRNA202 (Assay ID 001232) was used as
an endogenous control for miR-124 expression in mice as recommended by Applied
Biosystems [447]. The fold-change in expression was calculated by using the
comparative Ct (ΔΔCt) method, with the values of controls set to 1. All samples were
tested in quadruplicate. The Cancer miRNAs Transcriptome PCR Array (SABiosciences, MD) was used to identify potential miRNAs that target NR4A1. The array
was provided by the manufacturer in a 96-well PCR plate, each well containing cDNA
sample synthesized from HeLa cells treated with one of 90 cancer-related miRNA
mimics. According to the manufacturer’s instruction, we added qPCR MasterMix and
NR4A1 probe and performed qPCR. We used the data analysis software provided by
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SABiosciences to analyze qPCR data and determine which miRNAs affect NR4A1
expression.
miR-124 inhibitor assay
Daoy cells were plated at a density of 100,000 cells per well in 6-well BD Falcon
plates (Corning, Corning, NY). After 24 hours, the cells were first transfected with
various concentrations of the miR-124-3p inhibitor (single-stranded RNA molecule) or
the control oligonucleotide (oligo) for 24 hours at 37°C and then transfected with 1 μg of
the NR4A1-3ʹUTR-Luc reporter plasmid. Transfecting the miR-124-3p inhibitor first
allowed it to sufficiently inhibit the miR-124 activity before transfection of the NR4A13ʹUTR-Luc reporter plasmid. After 24 hours of incubation, the cells were reseeded at a
density of 4,000 cells per well in a 96-well plate, with 6 wells used for each condition.
The DualGlo reporter assay was performed 48 hours later. The mirVana inhibitor from
Life Technologies and the Power inhibitor from Exiqon (Woburn, MA) were both used to
obtain the inhibitor data as indicated in the figure legends; each was used with a control
oligo from their respective manufacturers. The Lipofectamine RNAiMAX transfection
reagent (Life Technologies) was used with both inhibitors.
Transfections
Cells were transfected with miRNAs by using Fugene6 (Promega) in Opti-MEM
in combination with antibiotic-free media (corresponding to the cells being transfected).
The plasmid containing pre-miR-124-1 and its backbone vector pEZX-MR03 were
purchased from GeneCopoeia.
For the NR4A1 and miR-124 co-transfection assay, Daoy cells were seeded at a
density of 100,000 cells per well in a 6-well BD Falcon plate. After 24 hours, cells were
transfected with 1 µg NR4A1 with or without its 3ʹUTR. Cells were transfected with 2.5
µg miR-124 or its control vector (MR03) 24 hours later and collected for Western blot
analysis 48 hours after that.
For NR4A1-knockdown assays, Daoy cells were seeded at a density of 250,000
cells in T25 flasks. Once the cells were 60%-70% confluent, they were transfected with
20 nM siNR4A1 by using Dharmacon siGENOME siRNA (GE Healthcare, Lafayette,
CO) and 8 μL of RNAiMAX. After 48 hours, cells were reseeded for viability and
proliferation assays. The SMARTpool siNR4A1 (Catalog # M-003426-04) and the
individual siNR4A1 (Catalog # D-003426-23) were both used as indicated in the figure
legends. Non-targeting siRNA #4 (Catalog # D-001210-04-20) was used as a control for
both the pooled and individual siRNAs.
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Molecular cloning
NR4A1 cDNA was cloned into the pEXM12-3XFLAG (N-terminal) vector
(GeneCopoeia). Forward (5ʹ– ATACTAGTCCACCATGGACTACAAAGACC –3ʹ) and
reverse (5ʹ– ATG AAT TCC TAG AAG GGC AGC GTG TC –3ʹ) primers were used to
PCR-amplify 3XFLAG-NR4A1 cDNA from the pEXM12-3XFLAG-NR4A1 vector. The
NR4A1 PCR product was then cloned into the pCR2.1 TOPO vector by using the TOPO
TA Cloning Kit (Life Technologies). The product was then digested by using SpeI and
EcoRI restriction enzymes (New England BioLabs, Ipswich, MA) and ligated into a
pSIN-EF2-IRES-Blast lentiviral expression vector to generate pSIN-NR4A1. The pSIN
vector originated from Addgene (Plasmid #16578, [460]) but was modified by inserting
additional enzyme sites and the BlastR gene (for resistance to blasticidin).
To generate a pSIN-NR4A1-3ʹUTR construct, the 3ʹUTR of NR4A1 was cloned
from the NR4A1-3ʹUTR reporter plasmid (GeneCopoeia) and inserted into the 3ʹUTR
region downstream of the NR4A1 coding sequence in the pSIN-NR4A1 vector. Briefly,
the 3ʹUTR sequence was amplified by using forward (5ʹ–
ATGAATTCCCCCTGCCTGGGAA –3ʹ) and reverse (5ʹ–
ATGGATCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCAACTACATGT –3ʹ)
primers. This 3ʹUTR PCR insert was electrophoresed on a gel, and the band was gelpurified by using the Qiagen gel extraction kit. The purified 3ʹUTR insert was then
cloned into the pCR2.1 TOPO vector (Life Technologies). The TOPO and pSIN plasmids
were digested by using EcoRI and BamHI (New England BioLabs), and the 3ʹUTR
segment was ligated into the pSIN-NR4A1 vector. All primers were synthesized by
Invitrogen; all PCR amplifications were performed by using the Phusion High-Fidelity
PCR Master Mix with HF Buffer (New England BioLabs); and the sequences of all final
DNA constructs were confirmed by performing Sanger sequencing.
Protein isolation and Western blot analysis
Cells were incubated with Pierce RIPA lysis buffer (Thermo Fisher Scientific,
Grand Island, NY) on ice for 20 minutes and centrifuged at 17,500 g for 20 minutes. The
supernatant was collected, and its protein concentration was measured by using a Pierce
BCA Protein Assay kit. Absorbance at 540 nM was measured by using the SpectraMax
M5 microplate reader (Molecular Devices, Sunnyvale, CA). The protein was mixed with
10X loading buffer and 4X LDS (Life Technologies), incubated at 95°C for 5 minutes,
and loaded into a NuPAGE 4-12% Bis-Tris gel (Life Technologies). The separated
protein was then transferred to a nitrocellulose membrane by using an iBlot transfer
system (Invitrogen). The blot was blocked at room temperature for one hour by using
Odyssey blocking buffer (LI-COR Biosciences, Lincoln, NE). Mouse monoclonal antiFlag M2 (Sigma; catalog # F1804-5MG; used at 1:1500 dilution) and mouse monoclonal
anti-β-actin (Sigma; A5441; used at 1:2000 dilution) antibodies were added and
incubated overnight at 4°C. After the primary antibodies were removed, the blot was
washed three times with TBST for 15 minutes each time before being incubated with the
secondary antibody for 1 hour at room temperature. After 1 hour, the blot was washed
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three times, and proteins were detected by using the Odyssey imaging system (LI-COR
Biosciences). ImageJ [461] was used to measure band intensity.
Lentivirus production and transduction
Two million 293T cells were seeded into each 10-cm dish. Once the cells reached
approximately 90% confluence, they were transfected with 12 μg of the expression
plasmid, 3 μg of the VSV-G envelope-expressing plasmid pMD2.G (Addgene, Plasmid
#12259), and 6 μg of the 2nd-generation lentiviral packaging plasmid psPAX2 (Addgene,
Plasmid #12260) by using 60 μL FuGENE6 (Promega) in OptiMEM. Media were
replaced with fresh media 24 hours after transfection. The lentivirus supernatant was
collected 48 hours after media replacement and filtered through a 0.45-μM filter and
titrated by using Lenti-X GoStix (Clontech Laboratories, Mountain View, CA). In cases
of low titer, Lenti-X Concentrator (Clontech Laboratories) was used to increase the
lentiviral titer.
To exogenously express NR4A1, Daoy cells were seeded at a density of 250,000
cells in T25 flasks. Once the cells were 60%-70% confluent, they were transduced with
NR4A1 lentivirus; Polybrene (AmericanBio, Natick, MA) was used at 0.8 μL/mL to aid
transduction efficiency. After 48 hours, cells were reseeded for viability and proliferation
experiments.
Viability assay
Cells were reseeded at a density of 1000 cells per well in 96-well plates, with 5
replicates of each condition. Cell viability was determined by using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega): cells were incubated with 100 μL of the
reagent for 20 minutes on a shaker, covered with a dark lid. Luciferase activity was
measured by using the EnVision 2101 Multilabel Reader (PerkinElmer) on the day the
cells were seeded (day 0) and daily after that for 3-4 days. The day 1 through day 4
viability measurements were normalized to that measured on day 0. The initial seeding
density of 1000 cells per well was chosen so that cells would be close to but less than
100% confluent by the final day.
Crystal violet staining
Cells were reseeded in 12-well plates at a concentration of 15,000 cells per well,
with 4 replicates of each condition. After removing the media and washing with PBS, we
fixed the cells in 4% formaldehyde (Sigma-Aldrich, St. Louis, MO) and gently rocked
them for 10 minutes at room temperature. The formaldehyde was then removed, and the
cells were washed twice with PBS, incubated with 1% crystal violet (Sigma-Aldrich)
while gently rocking for 10 minutes at room temperature, and then rinsed with water until
the water washed clear, after which 0.1% SDS was added and incubated for 10 minutes
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while gently rocking. The absorbance of each well was then measured at 590 nm by using
a SpectraMax M5 (Molecular Devices). Crystal violet staining was performed on the
same day as the initial cell seeding (day 0) and daily thereafter for 3-4 days. Crystal
violet absorbance readings measured on days 1-4 were normalized to that measured on
day 0.
IncuCyte proliferation assays
Cells were reseeded in a 24-well plate at a concentration of 10,000 cells per well,
with 4 replicates of each condition. Cell proliferation was monitored by using an
IncuCyte live-cell imaging system (Essen BioScience, Ann Arbor, MI): 9 images were
captured in each well every 12 hours. The percentage of confluent cells was calculated by
using IncuCyte software.
Stable cell lines
Stable cell lines were prepared by plating 500,000 Daoy cells in 10-cm dishes.
After 24 hours, cells in antibiotic-free media were transfected with 10 μg of either pEZXMR03 (vector control) or pEZX-MR03-miR-124 in FuGENE6 diluted in OptiMEM. The
media were replaced with normal growth media 24 hours after transfection. The cells
were treated with 1 μg/mL puromycin 24 hours after media replacement. Puromycin was
added every 3 days for 2 weeks until nontransduced control cells were completely killed
by the puromycin, after which the cells were considered to be stable. Expression of miR124 in the stable cells was confirmed by using a microscope to observe the GFP signal
expressed from the vector and by performing qPCR assays to quantify the levels of miR124.
3D-spheroid formation assay
Parental Daoy cells and Daoy cells stably expressing miR-124 or the control
vector (MR03) were seeded into a round-bottom 96-well plate at 3 different densities
(288, 800, and 2500 cells/well). Media were changed every 3-4 days, and spheroid areas
were calculated after 23 days by using the IN Cell Analyzer 6000 (GE). Viability was
also measured on day 23 by using the CellTiter-Glo 3D Cell Viability Assay (Promega)
according to the manufacturer’s protocol and shown as raw luminescence units (RLU).
Cerebellar granule neuron analysis
Cerebellar granule neurons (CGNs) were prepared as described [462]. Briefly,
cerebella were dissected from the brains of P7 C57BL/6 mice, and pial layers were
removed; the tissue was treated with trypsin/DNase and triturated into a single-cell
suspension by using fine-bore Pasteur pipettes. The suspension was layered onto a
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discontinuous Percoll gradient and separated by centrifugation. The small-cell fraction
was then isolated. The resulting cultures routinely contained 95% CGNs and 5% glia.
The cultures were maintained in Basal Medium Eagle (BME; Life Technologies)
supplemented with glutamine and 10% horse serum. All animal experiments were
performed in accordance with a protocol approved by St. Jude Children’s Research
Hospital’s Institutional Animal Care and Use Committee. The animals were housed at
22−23ºC with a 12 h light/dark cycle and free access to food and water at the St. Jude
Animal Resources Center certified by the American Association for Accreditation of
Laboratory Animal Care. Animals were euthanized by decapitation for the preparation of
CGNs.
Statistical analysis
Results are shown as the mean ± standard error of the mean. The sample values
were compared to control values by using a two-tailed unpaired student’s t-test.
GraphPad Prism 6 software was used to graph results and to calculate the statistical
significance.
Results
Three miRNAs directly target NR4A1
To identify miRNAs that may target NR4A1, we used a luciferase reporter system
in which 293T cells were co-transfected with a reporter plasmid containing the 3ʹUTR of
NR4A1 along with our collection of 296 miRNAs. In the NR4A1-3ʹUTR-Luc reporter,
the firefly luciferase gene is directly upstream of the 3ʹUTR sequence: a miRNA that
binds to the 3ʹUTR will decrease the translation of the luciferase mRNA, resulting in
decreased luciferase activity being detected by the Dual-Glo Luciferase Assay System.
As shown in a waterfall plot (Figure 3-1A), miR-124 caused the greatest reduction in
luciferase levels among the 296 miRNAs tested. We selected 40 miRNAs that caused
40% or more reduction in luciferase activity and retested them in triplicate: 13 of the 40
miRNAs repeatedly decreased luciferase levels by 30% or more (Figure 3-1B).
In addition to using the luciferase reporter system, we used the Cancer miRNAs
Transcriptome PCR Array (as described in Materials and Methods), which contains
cDNA from HeLa cells transfected with one of 90 cancer-related miRNAs, many of
which were included in our collection of 296 miRNAs used in the luciferase reporter
screen. We found that miR-124 was one of the 3 miRNAs that substantially
downregulated NR4A1 (Figure A-1).
Among the miRNAs that downregulated NR4A1 (Figure 3-1A and B), only miR124, miR-15a, and miR-224 were predicted by multiple prediction algorithms to target
NR4A1 by binding to its seed region (a 5- to 8-nucleotide sequence within the 3ʹUTR that
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Figure 3-1. miR-124, miR-15a, and miR-224 directly target NR4A1.
(A) miR-124 caused the greatest decrease in luciferase activity after 293T cells were
transfected with a NR4A1-3ʹUTR-Luc reporter and one of 296 miRNAs. Each data point
on the waterfall plot corresponds to the resulting luciferase activity for each miRNA.
Renilla luciferase (RLuc) was used to normalize firefly luciferase (FLuc) activity. (B)
Thirteen miRNAs significantly (p < 0.001) reduced luciferase activity below that of the
pSIF control vector (average of 3 independent experiments is shown). (C) The seed
region where miR-124, miR-15a, and miR-224 are predicted to bind within the 3ʹUTR of
NR4A1 was mutated, and luciferase assays were performed to show direct targeting of
NR4A1 by these 3 miRNAs. The data shown are the average of 3 independent
experiments. * indicates p < 0.001.
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mediates the direct binding of a miRNA). These binding predictions are based on the
predicted seed regions found within the TargetScan database. When we mutated the
binding sites within the 3ʹUTR corresponding to seed regions for miR-124, miR-15a, and
miR-224, the mutated 3ʹUTR (124mut, 15mut, and 224mut) became resistant to the
corresponding miRNA (Figure 3-1C), demonstrating that these miRNAs directly target
NR4A1 by binding to a seed region within the NR4A1 3ʹUTR.
NR4A1 is upregulated in pediatric cancer cell lines
To further investigate the functional relationship between NR4A1 and its miRNA
regulators, we first analyzed the endogenous NR4A1 mRNA levels in several pediatric
cancer cell lines. These levels were significantly higher in rhabdomyosarcoma cells lines
RD, Rh41, and Rh30 than in LHCN-M2 immortalized myoblasts (Figure 3-2A). In
addition, NR4A1 expression in D341 and Daoy medulloblastoma cells and in NB3
neuroblastoma cells was upregulated compared to that of HCN-2 human cortical neurons
(Figure 3-2B). We further analyzed the endogenous expression of miR-124, miR-15a,
and miR-224 in Rh30, Daoy, and NB3 cells. As shown in Fig 2C, all 3 miRNAs were
downregulated in Daoy, and miR-224 was decreased in NB3 cells. Interestingly, miR-124
was upregulated in NB3, a MYCN-amplified neuroblastoma cell line [457], which is
consistent with a recent report showing miR-124 upregulation in MYCN-amplified
neuroblastoma when compared to nine other pediatric solid tumors including
rhabdomyosarcoma and non-MYCN-amplified neuroblastoma [463]. The mechanism
responsible for the upregulation of miR-124 in NB3 cells is unclear. miR-224 was
significantly downregulated in NB3 cells (Figure 3-2C), possibly contributing to the
upregulation of NR4A1 (Figure 3-2B). For the remainder of this study, we focused on the
relationship between miR-124 and NR4A1 in Daoy cells because miR-124 is highly
expressed in the brain [464] and it acts as a tumor suppressor in medulloblastoma [465467]. Furthermore, in undifferentiated granule neuron precursors (GNPs), the level of
Nr4a1 was high but that of miR-124 was low (Figure A-2). Interestingly, once these
GNPs differentiated, Nr4a1 was downregulated and miR-124 was upregulated
(Figure A-2). These observations led us to further investigate the functional relationship
between miR-124 and NR4A1.
miR-124 decreases NR4A1 expression
Compared to expression in HCN-2 cells, NR4A1 was upregulated and miR-124
was downregulated in Daoy cells (Figure 3-3A). We further investigated the inverse
correlation between NR4A1 and miR-124 expression by determining the effect of
modulating miR-124 levels on the levels of NR4A1. As shown in Fig 3B, higher levels of
miR-124 correlated with lower levels of NR4A1. Additionally, the NR4A1 3ʹUTR-Luc
activity increased after treatment with a miR-124 inhibitor, further validating the inverse
relationship between miR-124 and NR4A1 (Figure 3-3C). Another miR-124 inhibitor
(from Exiqon) was used, yielding similar results (Figure A-3). Exogenous
overexpression of miR-124 decreased the mRNA level of endogenous NR4A1 and that of
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Figure 3-2. NR4A1 is upregulated in pediatric cancer cell lines.
(A, B) NR4A1 mRNA expression is upregulated in rhabdomyosarcoma,
medulloblastoma, and neuroblastoma cell lines. Fold-change was calculated by
normalizing the mRNA expression levels to those of their respective control cell lines
(either LHCN-M2 or HCN-2), which were set to 1. (C) Endogenous miRNA expression
in Rh30, Daoy, and NB3 cells shows that all 3 miRNAs are downregulated in Daoy cells
and that miR-224 is downregulated in NB3 cells. RNU48 was used as an internal control.
All data shown are the average of 3 independent experiments; *p < 0.0001.
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Figure 3-3. miR-124 decreases NR4A1 levels.
(A) Endogenous expression levels of miR-124 and NR4A1 were measured in Daoy cells
and human cortical neurons (HCN-2). (B) NR4A1 and miR-124 expression are inversely
related in Daoy cells exogenously expressing various levels of miR-124. The levels of
NR4A1 and miR-124 changed in an inversely correlated manner. (C) Daoy cells were cotransfected with the NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTR-Luc) and either an
inhibitor of miR-124 (10 – 160 nM of oligonucleotide used as indicated) or an oligo
control (Cntrl) from Life Technologies; resulting luciferase levels were measured. The
data shown are representative of 3 independent experiments. (D) Either miR-124 or the
control vector (MR03) was exogenously expressed in Daoy cells, and the resulting levels
of miR-124 and NR4A1 were measured along with the expression of NR4A1 target genes.
(E) Daoy cells were co-transfected with miR-124 (124) or vector control (MR03) and
Flag-NR4A1 plasmid with (3ʹUTR) or without (NR4A1) the 3ʹUTR to confirm that miR124 targets the 3ʹUTR. Flag and actin protein levels were detected by Western blot and
quantified by using ImageJ. Levels of Flag protein were first normalized to those of actin;
then MR03-3UTR was set to 1, and all other samples were compared to this sample. The
Western blot shown is representative of 3 independent experiments, and the bar graph
shows the average protein fold-change from 3 experiments. * indicates p < 0.05.
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several target genes of NR4A1, including E2F1, CCND2 (cyclin D2), BIRC5 (survivin),
TXNDC5, CDK4, and STAT5A (Figure 3-3D). Furthermore, miR-124 overexpression
also decreased the expression of NR4A1 target genes in 293T cells (Figure A-4). To
demonstrate that elevated miR-124 decreases NR4A1 protein levels in a 3ʹUTRdependent manner we examined the effect of overexpressed miR-124 on a Flag-tagged
NR4A1 construct without the 3ʹUTR (NR4A1) or with the 3ʹUTR (3ʹUTR). As shown in
Figure 3-3E, overexpression of miR-124 decreased the level of Flag-NR4A1 only when
the 3ʹUTR of NR4A1 was present.
NR4A1 promotes cell viability and proliferation
Studies have shown that NR4A1 increases cell survival and proliferation in
various adult cancer cell lines, suggesting an oncogenic role for NR4A1 in those
particular cancers [230, 233, 239, 468-470]. We examined whether this was also the case
for pediatric cancer cell lines, specifically Daoy medulloblastoma cells. Upon exogenous
overexpression of NR4A1 in Daoy cells, there was increased cell viability as assessed by
the CellTiter-Glo assay (Figure 3-4A). Cell proliferation was measured by performing
crystal violet staining and using an IncuCyte live-cell imaging system, which monitors
real-time cell proliferation. Compared to cells transduced with the empty vector (EV), the
cells exogenously overexpressing NR4A1 showed increased crystal violet staining and
confluence over the course of 4 days (Figure 3-4B and C). Figure 3-4D shows the
elevated NR4A1 mRNA levels after transduction with NR4A1. These data support the
notion that NR4A1 promotes tumor growth not only in adult cancers but also in pediatric
solid tumors.
Knockdown of NR4A1 decreases cell viability and proliferation
To further validate the effects of NR4A1 on cell proliferation and viability,
NR4A1 was knocked down via pooled siRNA targeting NR4A1 (siNR4A1). Daoy cells
transfected with siNR4A1 exhibited decreased cell viability and proliferation as measured
by the CellTiter-Glo assay, crystal violet staining, and the IncuCyte assay
(Figure 3-5A-C and E). Figure 3-5D shows the knockdown efficiency. The 4 individual
siRNAs making up the pooled siRNA were then tested individually. siNR4A1_4 most
efficiently knocked down NR4A1 and caused the greatest decrease in cell viability and
proliferation (Figure A-5).
miR-124 decreases cell viability and proliferation
The observations that NR4A1 promoted cell proliferation (Figures 3-4 and 3-5)
and that miR-124 directly targeted and downregulated NR4A1 (Figure 3-3) led us to
examine the effects of miR-124 on cell viability and proliferation. Exogenous and stable
expression of miR-124 in Daoy cells substantially reduced cell viability and proliferation
(Figure 3-6A-C). To measure the ability of the Daoy cells to form microtumors, we used
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Figure 3-4. NR4A1 promotes cell viability and proliferation.
(A) Daoy cells were transduced with pSIN-NR4A1 (NR4A1) or pSIN vector (EV), and
cell viability was measured via the CellTiter-Glo assay every day for 4 days. Viability for
each day was normalized to that of Day 0 (0 hours), and statistical significance was
calculated for each day. (B) Cells were stained with crystal violet every day for 4 days to
measure proliferation over time. The absorbance was measured and normalized to that of
Day 0 (0 hours). The statistical significance was calculated for each day. (C) Cell
proliferation was monitored by using an IncuCyte live-cell imager for real-time imaging.
The resulting cell confluence was recorded every 12 hours for 4 days. (D) NR4A1 mRNA
level was measured after transduction with NR4A1. All experiments were performed by
using Daoy cells transduced with EV or NR4A1 lentivirus. All data shown are
representative of 3 independent experiments; *p ≤ 0.0001.
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Figure 3-5. NR4A1 knockdown decreases cell viability and proliferation.
(A) Daoy cells were transfected with 20 nM of the SMARTpool siNR4A1 or nontargeting control (NT), and cell viability was measured via the CellTiter-Glo assay every
day for 3 days. Viability for each day was normalized to that of Day 0 (0 hours), and
statistical significance was calculated for each day; *p < 0.0001. (B) Cells were stained
with crystal violet every day for 3 days to measure proliferation over time. The
absorbance was measured and normalized to that of Day 0 (0 hours). The statistical
significance was calculated for each day; *p < 0.01. (C) Proliferation was monitored via
the IncuCyte live-cell imager. Cell confluence was averaged, with 4 replicates of each
condition; *p < 0.0001. (D) NR4A1 was significantly (p < 0.0001) decreased after
transfecting Daoy cells with siNR4A1. (E) Images shown for each NT and siNR4A1
panel over 5 days are the same image view within the same well and are representative of
3 independent experiments with 4 wells for each condition. These images correspond to
the data in C. Data shown in A are representative of 5 independent experiments; data in B
are representative of 4 independent experiments, and data in C and E are representative of
2 independent experiments. Data shown in D is the average of 4 independent
experiments.
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Figure 3-6. miR-124 decreases cell proliferation in 2D and 3D cultures.
(A) Expression of miR-124 was significantly (p < 0.0001) increased after antibiotic
selection of Daoy cells transduced with pEZX-MR03-miR-124. As a result, NR4A1
mRNA levels were significantly decreased (p < 0.0001). Data shown are the average of 6
independent experiments. (B) The CellTiter-Glo assay was used to analyze the cell
viability of Daoy cells stably expressing exogenous miR-124 or vector control (MR03).
Viability for each day was normalized to that of Day 0 (0 hours), and statistical
significance was calculated for each day; *p < 0.0001. (C) Stable cells were imaged by
using the IncuCyte live-cell imager to determine cell proliferation over the course of 3.5
days, and statistical significance was determined for each day; *p < 0.0001. (D) Parental
Daoy cells (Daoy) and Daoy cells stably expressing exogenous miR-124 (miR-124) or its
control vector (MR03) were seeded at 3 densities (288, 800, and 2500 cells/well) and
grown using 3D culture techniques. After 23 days (left panel), the cells’ spheroid areas
(*p < 0.01) were measured by using the IN Cell Analyzer (middle panel). Viability
(*p < 0.05) was determined by performing CellTiter-Glo 3D Cell Viability Assays and is
shown as raw luminescence units (RLU) (right panel). The spheroid area data shown are
for cells seeded at an initial density of 800 cells per well. Data from B are representative
of 5 independent experiments; data from C are representative of 4 independent
experiments, and data from D are representative of 2 independent experiments.
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round-bottom 96-well plates to promote the formation of 3D spheroids. After allowing
the cells to form spheroids for 23 days, we found that cells exogenously overexpressing
miR-124 underwent less spheroid growth and viability than did the control cells (Figure
3-6D). These results are consistent with previously reported evidence showing the
negative effects of miR-124 on medulloblastoma cell growth [465-467].
Conclusions
To our knowledge, our study is the first to show that the level of NR4A1 is
regulated by miR-124 and that NR4A1 has roles in proliferation of pediatric cancer cells
such as Daoy medulloblastoma cells. Most published research on NR4A1 as a therapeutic
target involves using drugs to induce NR4A1-mediated apoptosis; our discovery that
miR-124 regulates NR4A1 suggests that it may be possible to modulate NR4A1 and
influence cancer cell growth by regulating miR-124.
In a panel of pediatric cancer cell lines, we found NR4A1 to be upregulated in all
cell types including RD, Rh41, and Rh30 RMS cells, D341 and Daoy medulloblastoma
cells, and NB3 neuroblastoma cells. We identified 3 miRNAs that directly target NR4A1,
including miR-124, miR-15a, and miR-224, all of which were downregulated in Daoy,
demonstrating an inverse correlation between NR4A1 and the miRNAs that target it.
However, we did not observe this trend in the other cell types. There are most likely
additional miRNAs that target NR4A1 in the other cell types and perhaps this is why we
did not see a correlation.
It is difficult to conclusively determine the role of NR4A1 in medulloblastoma
based on these studies as Daoy cells are not classified as any of the 4 subtypes of
medulloblastoma. Furthermore, there is not substantial evidence in expression databases
demonstrating whether or not NR4A1 is upregulated in patients with medulloblastoma.
Therefore, further studies showing expression levels of NR4A1 in medulloblastoma are
required in order to make this determination. Furthermore, tumorigenicity assays such as
soft agar colony formation assays that test anchorage independent growth can be
performed in multiple medulloblastoma cell types that more closely resemble the
different subtypes of medulloblastoma. The tumorigenic potential of NR4A1 can also be
tested in vivo wherein NR4A1 can be overexpressed in a medulloblastoma cell line that is
then injected into mice and the resulting tumors are measured to determine if NR4A1
promotes the growth of medulloblastoma tumors. Additionally, knockdown studies can
be conducted in vivo to conclusively confirm whether or not NR4A1 affects the growth
rate of medulloblastoma tumors.
Interestingly, we found that NR4A1 expression decreases while miR-124
expression increases in differentiating GNPs. This supports previous research showing
that miR-124 expression is higher in differentiated GNPs compared to undifferentiated
GNPs. The decrease in NR4A1 expression suggests that NR4A1 must be downregulated,
possibly by miR-124, in order for differentiation to occur. It is of interest to explore the
function of NR4A1 in GNPs as these are the main type of neuron in the cerebellum where
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a subtype of medulloblastoma originates. A more thorough discussion on this topic can
be found in Chapter 5.
In short, we found that miR-124 targets and decreases NR4A1 expression and
function. NR4A1 promotes cell proliferation in Daoy medulloblastoma cells, but miR124 reduces it, in part by targeting NR4A1 and decreasing its transcriptional activity. This
results in decreased expression of NR4A1 target genes important in cell cycle progression
and survival. This study supports the use of miRNA mimics to treat cancers, especially
those in which NR4A1 has an oncogenic role.
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CHAPTER 4.

THE ROLE OF NR4A1 IN SKELETAL MUSCLE
DIFFERENTIATION
Introduction

Diseases related to muscle such as Duchenne muscular dystrophy and
rhabdomyosarcoma, which are prevalent in children, are in desperate need of effective
treatments. In order to develop therapies, it is critical to understand normal muscle
development and function. The process of muscle formation, termed myogenesis,
involves several stages including proliferation, migration, and differentiation. During the
first stage, mesodermal progenitors exit the cell cycle and several transcription factors
appear including Pax3, Pax7, Myf5, and MyoD1. These transcription factors are required
for the cells to become myoblasts. These myoblasts will then align with one another and
become myocytes after the expression of additional transcription factors including
myogenin (MYOG) and Myf6. During the final stages of differentiation, the myocytes
will fuse to form multinucleated myotubes, which will then become muscle fibers.
Additional muscle markers such as myosin heavy chain (MHC/MYH) and muscle
creatine kinase (CKM) become expressed in the later stages of differentiation [471-473].
NR4A1 has many physiological roles in various tissues such as its involvement in
muscle function. For example, Nr4a1 promotes glucose and oxidative metabolism in
skeletal muscle and has even been shown to promote myofiber size and muscle mass in
mice [148, 474, 475]. However, the role of NR4A1 during human skeletal muscle
differentiation is not well understood. For these studies, we utilized primary SkMC and
HSMM as well as immortalized LHCN human skeletal muscle cells. In this study we
found that NR4A1 expression increases during the myogenic program in LHCN, and
knockdown of NR4A1 results in decreased expression of myogenic markers in all 3 cell
types. This suggests that NR4A1 participates in skeletal muscle differentiation.
In addition, ZNF148 may regulate NR4A1 during myogenesis by suppressing its
expression. Knockdown of ZNF148 in LHCN rapidly induced the formation of myotubes
with a resulting increase in NR4A1 expression. Understanding these mechanisms may be
beneficial in cancer since certain malignancies such as rhabdomyosarcoma result from
the failure of cells to differentiate and instead proliferate uncontrollably, leading to tumor
formation and cancer progression.
Methods
Cell culture
LHCN-M2 (LHCN) cells are human skeletal myoblasts [458] and were grown in
flasks coated with extracellular matrix (0.2% MaxGel ECM in PBS from Sigma-Aldrich)
and cultured in DMEM supplemented with 15% FBS, 0.02M HEPES, 0.03 µg/mL zinc
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sulfate, 1.4 µg/mL vitamin B12, 0.055 µg/mL dexamethasone, 2.5ng/mL hepatocyte
growth factor (recombinant human), 10 ng/mL basic fibroblast growth factor, and 1%
penicillin-streptomycin (Life Technologies, Carlsbad, CA). Differentiation was induced
by the addition of differentiation media, which consisted of DMEM supplemented with
0.02M HEPES, 0.03 µg/mL zinc sulfate, 1.4 µg/mL vitamin B12, 10 µg/mL insulin, 100
µg/mL apo-transferrin, and 1% penicillin-streptomycin. Human skeletal muscle cells
(SkMC) and myoblasts (HSMM) were purchased from Lonza (Walkersville, MD) and
originate from gestational tissue and adult tissue, respectively. They were cultured in
SkGM-2 Skeletal Muscle Cell Growth Medium-2 (BulletKit from Lonza) and were
differentiated by adding 2% horse serum to DMEM/F-12 media (Lonza). All cells were
cultured at 37°C in 5% CO2.
Transfection
LHCN were plated at 100k cells/well in 6-well plates coated with ECM. After 24
hours they were transfected with 10 nM non-targeting control (NT) or siRNA for NR4A1
(siNR4A1) and 5 ul RNAiMAX (in 300 ul of OptiMEM). Media was replaced with fresh
media 24 hours after transfection. Differentiation media was added once the cells reached
100% confluence, which was typically 72 hours post-transfection. Media was replaced
every 2 days during the course of differentiation. For knockdown of ZNF148, cells were
transfected with 10 nm control (Cntrl) or siZNF148 (Cat. # D-012658-04). Reagents for
siRNA were purchased from Dharmacon using their siGENOME siRNA (GE Healthcare,
Lafayette, CO). For both siNR4A1 and siZNF148, the knockdown efficiency was
approximately 90%, and 3 out of 4 of the individual siRNAs had a similar phenotype,
indicating that they are specific to their respective target genes. SkMC and HSMM were
plated at 150k cells/well in 6-well plates and were transfected 48 hours after plating.
Once cells reached 70-80% confluence, differentiation was induced by the addition of
differentiation media, which was replaced every 2 days.
RNA extraction and qPCR
RNA was extracted by using the Maxwell 16 LEV simplyRNA Tissue Kit in
conjunction with the Maxwell 16 Research Instrument (Promega). The resulting RNA
concentration was measured by using the NanoDrop and was subsequently converted to
cDNA by using the SuperScript VILO cDNA Synthesis Kit (Life Technologies). Target
gene mRNA expression was detected by using specific Taqman probes (20X) and
quantitated via the 7900HT Fast Real-Time PCR System (Applied Biosystems). 18S
(Assay ID Hs99999901_s1) was used as an endogenous control for all gene expression
analysis, including NR4A1 (Assay ID Hs00374226_m1), MYOG (Assay ID
Hs01072232_m1), MYH2 (Assay ID Hs00430042_m1), CKM (Assay ID
Hs00176490_m1), and ZNF148 (Assay ID Hs01070570_m1).
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Protein isolation and Western blot analysis
Cell pellets were lysed in Pierce RIPA lysis buffer (Thermo Fisher Scientific,
Grand Island, NY) and incubated on ice for 30 minutes prior to sonication for 5 s and
finally centrifugation at 17,500 g for 5 minutes. The protein concentration was measured
by using a Pierce BCA Protein Assay kit and absorbance was measured at 540 nM by
using the SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, CA). The
protein lysate was mixed with 10X loading buffer and 4X LDS (Life Technologies) and
incubated at 95°C for 5 minutes. Subsequently, the protein mixture was loaded into a
NuPAGE 4-12% Bis-Tris gel (Life Technologies) and run at 100 V for 2 hours. The
protein was then transferred to a PDVF membrane using the slow transfer method. This
method involves activation of the PDVF membrane with methanol for 10 minutes
followed by incubation in transfer buffer to remove the methanol. The protein was
transferred to the PDVF membrane overnight on ice at 0.45 amperes. The blot was then
blocked at room temperature for one hour by using Odyssey blocking buffer (LI-COR
Biosciences, Lincoln, NE). Mouse monoclonal anti-MHC (produced using hybridoma
cells from the Developmental Studies Hybridoma Bank; used at 1:200 dilution), mouse
monoclonal anti-myogenin (Santa Cruz; used at 1:500), and mouse monoclonal anti-βactin (Sigma; A5441; used at 1:2000 dilution) antibodies were added and incubated
overnight at 4°C. After the primary antibodies were removed, the blot was washed with
TBST three times for 15 minutes each time prior to incubation with the secondary
antibody (LI-COR Biosciences; used at 1:10,000 dilution) for 1 hour at room
temperature. Subsequently, the blot was washed three times with TBST and proteins were
detected by using the Odyssey imaging system (LI-COR Biosciences).
Immunofluorescence
Cells were washed 3 times with PBS and fixed with 2% paraformaldehyde for 15
minutes at room temperature followed by additional washes with PBS. The cells were
then permeabilized with 0.1% Triton X-100 for 15 minutes followed by 3 washes with
PBS. The monolayer was then washed 5 times with 0.5% BSA diluted with PBS (PBB)
and blocked with 2% BSA for 45 minutes followed by 5 washes with PBB. The primary
antibody for myosin heavy chain 1 (MHC) was added at a 1:100 dilution overnight at 4°C
and then washed 5 times with PBB. The secondary antibody was used at a 1:500 dilution
and incubated for 1 hour at room temperature followed by 5 washes with PBB. DAPI was
added at a 30,000 dilution of 1mg/ml for 5 minutes followed by 5 washes with cold PBS.
The chambers were then removed and mounted with coverslips and mounting media and
imaged using a Nikon Eclipse Ti microscope.
Statistical analysis
Results are shown as the mean ± standard error of the mean. Significance was
determined by using a two-tailed unpaired student’s t-test to compare the sample values
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to the control values. GraphPad Prism 6 software was used to graph results and to
calculate the statistical significance.
Results
NR4A1 expression increases during LHCN myogenesis
To determine if NR4A1 plays a role during myogenesis, expression was analyzed
during the differentiation of LHCN, SkMC, and HSMM human skeletal muscle cells.
NR4A1 mRNA levels increased by about 4 fold during the differentiation of LHCN,
however it did not substantially increase in SkMC and HSMM cells. To verify that the
cells were indeed differentiated, the myogenic markers MYOG, MYH2, and CKM were
measured (Figures 4-1, 4-2, and 4-3). MYOG is considered an early marker whereas
MYH2 and CKM are late differentiation markers. In order to determine if the other
NR4A family members are playing a role, the mRNA levels of NR4A2 and NR4A3 were
measured in all 3 cell types. NR4A2 was greatly decreased in LHCN and SkMC but not in
HSMM, whereas NR4A3 was increased in all 3 cell types. This suggests that NR4A2 may
inhibit differentiation while NR4A3 may promote it.
NR4A1 knockdown delays differentiation
To determine the significance of the increased NR4A1 expression in LHCN,
NR4A1was knocked down via siRNA (siNR4A1). As a result, differentiation was
severely delayed as shown by the decrease in differentiation markers and the visible lack
of myotube formation (Figure 4-4B-D). Protein levels for MYOG and MHC were also
extremely decreased in the cells lacking NR4A1 (Figure 4-4E). Bright-field images of the
cells clearly show well-differentiated NT cells by Day 4 compared to the siNR4A1 cells
that did not form myotubes (Figure 4-4F). Interestingly, NR4A1 expression was induced
up to 15 fold by Day 5 in the cells transfected with the non-targeting (NT) control
(Figure 4-4A). This is a much larger induction compared to the untransfected LHCN in
Figure 4-1A. Similar results were observed in SkMC and HSMM, however the NR4A1
mRNA levels actually decreased during differentiation in the NT cells
(Figures 4-5 and 4-6).
ZNF148 knockdown induces differentiation
Studies from our lab have demonstrated that knockdown of the transcription
factor ZNF148 rapidly induces differentiation in LHCN cells, suggesting that ZNF148
plays an inhibitory role during myogenesis. One study has shown that ZNF148 can
suppress the expression of NR4A1 by directly binding to its promoter [446]. To determine
the functional significance of this inhibitory mechanism, ZNF148 was knocked down via
siRNA in LHCN cells which resulted in the rapid formation of myotubes by Day 2
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Figure 4-1. NR4A1 expression increases during LHCN differentiation.
(A-F) LHCN were differentiated for 5 days with cells collected for each day beginning
on Day 0 when differentiation media is added. The mRNA levels for NR4A1, NR4A2,
NR4A3, myogenin (MYOG), myosin heavy chain (MYH2), and muscle creatine kinase
(CKM) were measured and normalized to Day 0, which was set to 1. Data shown is the
average of at least 2 independent experiments. * indicates p < 0.01.
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Figure 4-2. NR4A1 expression does not increase during SkMC differentiation.
(A-F) SkMC were differentiated for 5 days with cells collected every day beginning on
Day 0 when differentiation media was first added. The mRNA levels of NR4A1, NR4A2,
NR4A3, MYOG, MYH2, and CKM were measured and normalized to Day 0, which was
set to 1. Data shown is the average of 5 independent experiments. * indicates p < 0.05.
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Figure 4-3. NR4A1 expression does not increase during HSMM differentiation.
(A-F) HSMM were differentiated for 5 days with cells collected every day beginning on
Day 0 when differentiation media was first added. The mRNA levels of NR4A1, NR4A2,
NR4A3, MYOG, MYH2, and CKM were measured and normalized to Day 0, which was
set to 1. Data shown is the average of at least 2 independent experiments. * indicates
p < 0.05.
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Figure 4-4. Knockdown of NR4A1 delays differentiation in LHCN.
(A-D) LHCN were transfected with 10 nm non-targeting control (NT) and siRNA for
NR4A1 (siNR4A1) prior to differentiation for 5 days with cells collected every day
beginning on Day 0. The mRNA levels of NR4A1 and differentiation markers were
measure and normalized to NT Day 0, which was set to 1. Data shown is the average of 3
independent experiments. (E) Protein levels for MHC, MYOG, and β-actin were detected
in a western blot. (F) Bright-field images with 10X magnification were taken on Days 0,
2, and 4 with representative images shown.
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Figure 4-5. NR4A1 knockdown delays differentiation in SkMC.
(A-D) SkMC were transfected with 10 nm NT and siNR4A1 prior to differentiation for 5
days. The mRNA levels of NR4A1 and differentiation markers were measured and
normalized to NT Day 0, which was set to 1. Data shown is the average of 3 independent
experiments. (E) Protein levels of MYOG and β-actin were measured in a western blot.
(F) Bright-field images at 10X magnification were taken on Days 0, 3, and 5 with
representative images shown.
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Figure 4-6. NR4A1 knockdown delays differentiation in HSMM.
(A-D) HSMM were transfected with 10 nm NT and siNR4A1 prior to differentiation for
5 days. The mRNA levels of NR4A1 and differentiation markers were measured and
normalized to NT Day 0, which was set to 1. Data shown is the average of 2 independent
experiments.
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(Figure 4-7C-D). Interestingly, knockdown of ZNF148 induced differentiation in the
presence of growth media, demonstrating the strong repressive power of endogenous
ZNF148 in the control cells (Figure 4-7A). Accordingly, NR4A1 expression was also
induced more than 15 fold in the cells with siZNF148 under growth conditions and more
than 10 fold under differentiation conditions (Figure 4-7B).
Conclusions
In all, we discovered a novel role for NR4A1 in skeletal muscle differentiation.
NR4A1 expression increases during the myogenic program in LHCN, and knockdown of
NR4A1 results in decreased expression of differentiation markers in LHCN, SkMC, and
HSMM human skeletal muscle cells. This supports a previous study showing that Nr4a1
increases during the differentiation of mouse C2C12 skeletal muscle cells [142, 476].
However in that study, they noted that differentiation still occurred in the absence of
Nr4a1. Perhaps the difference in our results depends on the species and cell type as those
studies were conducted in murine cells whereas these studies were performed in human
cells.
Although NR4A1 was increased in LHCN, it was not increased in SkMC or
HSMM. This could be an artifact of the immortalized state of LHCN, whereas SkMC and
HSMM are primary cells. We would expect NR4A1 to have similar expression patterns
in LHCN and HSMM since these two cell types both originate from adult tissue, whereas
SkMCs are isolated from gestational tissue. Another difference in cell type is that SkMCs
are precursors and therefore less differentiated, whereas HSMM and LHCN are
myoblasts committed to becoming muscle. Even though NR4A1 was not increased in
SkMC and HSMM, knockdown of NR4A1 in these cells still resulted in decreased
expression of myogenic markers. Therefore it would appear that NR4A1 is important
during myogenesis. It was also interesting to observe the higher induction of NR4A1 in
cells transfected with NT. Perhaps there are some off target effects of the NT that
inadvertently increase NR4A1 levels. It would be reasonable to test additional NT
controls to determine if these effects are specific to the original NT used here.
Furthermore, we found that NR4A2 was decreased during the differentiation of LHCN
and SkMC while NR4A3 was increased in all 3 cell types. This suggests that NR4A2
overexpression should hypothetically inhibit differentiation while NR4A3 overexpression
should promote it. Perhaps the NR4A family has synergistic effects where myogenesis is
enhanced upon NR4A2 knockdown and NR4A1 and NR4A2 overexpression.
Since there are several stages of differentiation, it is of interest to determine the
stage in which NR4A1 is acting. Perhaps it is promoting the initial stages of cell cycle
arrest, or maybe it is mainly functioning during a later stage. One way to elucidate this
would be to determine the differentiation and fusion indices. The differentiation index is
a measure of the number of nuclei in myosin-positive cells which indicates how
differentiated the cells are whereas the fusion index is a measure of the number of nuclei
in each myotube, indicating the ability of myoblasts to fuse into myotubes [477].
Calculating these indices would help determine the effect of NR4A1 on how well the
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Figure 4-7. Knockdown of ZNF148 rapidly induces differentiation in LHCN.
(A-C) LHCN cells were transfected with 10 nM Cntrl or siZNF and cultured in either
growth (G1, G3) or differentiation (D1, D3) media with cells collected on Days 1 and
Day 3. The resulting mRNA levels of MYH2, ZNF148, and NR4A1 were measured and
normalized to Cntrl G1, which was set to 1. (D) Immunofluorescence was performed to
detect MHC (green) and DAPI (blue) in cells with ZNF148 knocked down. Images
shown are 20X magnification and were taken 2 days after the addition of differentiation
media.
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cells are able to differentiate and fuse. It is possible that knocking down NR4A1 is
blocking or delaying myoblast fusion without effecting differentiation.
On the other hand, NR4A1 may actually be more involved in the metabolism
aspect. Upon knockdown of NR4A1 in LHCN, SkMC, and HSMM, the muscle marker
CKM is dramatically downregulated whereas the other muscle markers MYOG and
MYH2 are only modestly decreased. Many studies have shown that CKM is an essential
enzyme during energy homeostasis and mediates the synthesis of creatine phosphate
(CrP) and ADP by transferring the gamma phosphate from ATP. During intense exercise
when there is a high demand for energy, CKM will then synthesis ATP from CrP and
ADP [478]. As expected, decreased CKM contributes to the gradual loss of muscle mass
and function during aging in vivo [478, 479]. As mentioned, NR4A1 has been shown to
promote glucose and oxidative metabolism in murine skeletal muscle [148, 474].
Therefore, it is quite possible that the role of NR4A1 in muscle is primarily related to
metabolism. To confirm this, expression of additional genes involved in metabolism
should be analyzed upon knockdown or overexpression of NR4A1 during the
differentiation of LHCN, SkMC, and HSMM cells.
Interestingly, knockdown of ZNF148 resulted in elevated levels of NR4A1 as well
as rapid formation of myotubes, even in the absence of differentiation growth factors.
This most likely occurs by the direct repression of NR4A1 by ZNF148 at the promoter of
NR4A1 as previously shown in pancreatic β-cells. This demonstrates a possible
mechanism by which ZNF148 and NR4A1 may be controlling skeletal muscle
differentiation. These results also highlight ZNF148 as a therapeutic target in diseases
such as RMS where the cells have failed to differentiate.
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CHAPTER 5.

DISCUSSION*

Regulation of NR4A1 by miRNAs in Cancer
The regulation of NR4A1 by miRNAs was previously unknown, and the function
of NR4A1 in pediatric cancers is currently undetermined. In this study, we found that
miR-124 directly targets NR4A1 and that NR4A1 is upregulated in multiple pediatric
cancer cell lines, including rhabdomyosarcoma, neuroblastoma, and medulloblastoma
cell lines. We focused on elucidating the function of NR4A1 and miR-124 in
medulloblastoma cells, and showed that exogenous expression of miR-124 in Daoy
medulloblastoma cells decreased the cells’ proliferation and viability.
Several previous reports suggest that miR-124 might also regulate NR4A1
indirectly. In pancreatic beta-cells, Sp1 binds to the promoter of NR4A1 and increases
NR4A1 levels [480]. Interestingly, during neuronal differentiation of mesenchymal stem
cells, miR-124 targets Sp1 mRNA and decreases Sp1 expression [481]. The results of
these studies suggest that miR-124 may indirectly decrease NR4A1 expression by
decreasing Sp1. In addition, NR4A1 binds to the promoter of several target genes,
including E2F1, CCND2 (cyclin D2), BIRC5 (survivin), TXNDC5, CDK4, and STAT5A
[231, 233, 438, 439]. Consistent with these reports, we showed that overexpression of
miR-124 decreased expression of these 6 target genes. By promoting expression of these
genes, NR4A1 exerts its effects on cell proliferation and survival. Aberrant
overexpression of NR4A1 can, therefore, lead to tumor growth and cancer progression.
Figure 5-1 summarizes our discovery of the miR-124/NR4A1 functional relationship in
the context of relevant previous reports.
Medulloblastoma is a highly malignant primary brain tumor that originates in the
cerebellum. It is also the most common malignant brain tumor in children, with patients
having a 50%-80% chance of survival depending on the specific tumor type and other
factors [482, 483]. There are 4 subgroups of medulloblastoma: Wnt, Shh, Group 3, and
Group 4 [484]. A study profiling miRNAs in Shh MB tumors found 30 miRNAs that
were downregulated in tumors with high Gli1, one of which was miR-124 [485]. Another
miRNA profiling study also found that miR-124 in a Shh MB mouse model was
downregulated compared to that in 1-month-old cerebella [486]. Furthermore, a study
profiling 19 human medulloblastomas found that miR-124 was downregulated in the
Wnt- and Shh-associated MBs [487]. Additionally, one study of miRNA profiles in 34
human primary medulloblastomas found that miR-124 was downregulated (subtypes
were not specified) [488].
--------------------*Modified with permission from PLOS ONE. Tenga, A., et al., Regulation of Nuclear
Receptor Nur77 by miR-124. PLOS ONE, 2016. 11(2): p. e0148433.
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Figure 5-1. Overview of NR4A1 regulation by miR-124.
NR4A1 can be directly targeted by miR-124, as revealed by our studies reported here
(indicated by the red line), or indirectly affected by miR-124 via Sp1. NR4A1 may act
through several downstream target genes to promote cell proliferation and survival.
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Interestingly, miR-124 is the most abundant miRNA in the brain [464] and
functions to promote neuronal differentiation [489], regulate neural stem cells [490], and
induce differentiation in glioma stem cells [491]. Pierson et al. first showed that miR-124
targets CDK6 in medulloblastoma cell lines and that miR-124 is downregulated in
medulloblastoma cells lines and tumors [465]. Silber et al. went on to show that miR-124
inhibits proliferation of medulloblastoma cells via cell-cycle arrest during G1 and that
these results are more dramatic in cells with higher CDK6 levels. Importantly, inducible
overexpression of miR-124 in vivo significantly reduced tumor growth generated by
subcutaneous injection of D425 medulloblastoma cells [467]. Li et al. also found
downregulation of miR-124 in 29 medulloblastomas and showed that miR-124 targets
SLC16A1, which functions to efflux lactic acid during aerobic glycolysis. The authors
suggest that inhibition of SLC16A1 by miR-124 decreases intracellular pH to a lethal
level, leading to the observed growth inhibition in medulloblastoma cell lines upon
overexpression of miR-124 [466]. It is clear that miR-124 has an important tumorsuppressive role in medulloblastoma and that it acts through various target genes. Our
research provides, for the first time, an additional target gene of miR-124, NR4A1, which
has known oncogenic roles in adult solid tumors.
As summarized in Figure 5-1, miR-124 may also indirectly downregulate NR4A1
by directly targeting the mRNA of Sp1, resulting in reduced Sp1 and NR4A1 levels.
Additionally, miR-124 is predicted to target CCND2 and TXNDC5, which are both target
genes of NR4A1. Furthermore, miR-124 is predicted to target RXRA (RXRα) and GSK3B
(GSK3β). RXRα and NR4A1 heterodimerize and either translocate to the mitochondria to
induce apoptosis or bind to the promoters of NR4A1 target genes to modulate
transcription [162, 175]. GSK3β suppresses NR4A1 activity by phosphorylating NR4A1
in colorectal cancer [418]. Therefore, it is possible for miR-124 to exert both positive and
negative effects directly and indirectly on NR4A1, depending on the specific cellular
context.
The main type of neuron that makes up the cerebellum is the granule neuron. We
found an inverse expression pattern whereby NR4A1 is upregulated and miR-124 is
downregulated in Daoy medulloblastoma cells and in undifferentiated murine GNPs.
Similar to Daoy medulloblastoma cells, in undifferentiated GNPs, the level of NR4A1 is
high and that of miR-124 is low. Once the GNPs differentiate into mature granule
neurons, NR4A1 levels drop dramatically and miR-124 expression increases. These
observations are consistent with those in studies showing that miR-124 promotes
neuronal differentiation [489-491] and that miR-124 levels in 1-month-old mouse
cerebellar tissue are higher than those in P6 GNPs [486]. The dramatic decrease in
NR4A1 expression after differentiation suggests that the levels of NR4A1 need to be
reduced before the cells can develop into mature neurons.
It is reasonable to hypothesize that increased levels of miR-124 are needed to
decrease NR4A1 for differentiation to occur. Aberrant downregulation of miR-124 might
block differentiation and promote tumorigenesis, warranting the future investigation of
the regulation of miR-124 levels. The miR-124 promoter has been reported to be
hypermethylated in pancreatic cancer [492], hepatocellular carcinoma [493, 494],
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ulcerative colitis, [495] and acute lymphoblastic leukemia [496]. It is therefore of interest
to analyze the promoter of miR-124 before and after differentiation to identify any
changes in methylation status and to identify proteins that may bind to the promoter of
miR-124, thereby affecting endogenous levels of miR-124.
NR4A1 can reportedly enhance neuronal outgrowth and differentiation: both
dibutyryl-cAMP (dbcAMP) and trichostatin A (TSA) promote neurite outgrowth in PC12
rat pheochromocytoma cells by inducing Nr4a1 expression via acetylated Lys14 of
histone H3, and knockdown of Nr4a1 inhibits dbcAMP and TSA-induced neurite
outgrowth [497, 498]. NR4A1 overexpression also promotes neurite formation in PC12
cells [498]. However, the opposite phenotype is observed in a murine macrophage cell
line. Oxidized low-density lipoprotein (oxLDL) induces mature macrophages to
differentiate into dendritic cells and induces NR4A1 expression in vascular cells.
However, when NR4A1 is overexpressed in RAW264.7 murine macrophages,
differentiation into dendritic cells is inhibited in the presence of oxLDL [499]. This
comes back to the key point that NR4A1 functions are heavily dependent on cellular
context, so it is possible for NR4A1 to have opposing functions in different tissues and
cell types.
Daoy cells are classified as desmoplastic cerebellar medulloblastoma [500];
however, researchers have found that this cell line does not mimic any of the 4 subtypes
of medulloblastoma. It would be useful to compare the expression level of NR4A1 in the
brain to that in medulloblastoma tumors, but unfortunately there are not substantial
published data showing NR4A1 levels in human medulloblastoma. However, two
databases show low basal expression of NR4A1 in healthy cerebellum. The Brain
Transcriptome Database shows that in situ hybridization images of the cerebellum have
very little NR4A1 signal [501]. In addition, the Genotype-Tissue Expression project
found that expression levels of NR4A1 in different parts of the brain, including the
cerebellum, were much lower than those in other normal tissue types [502]. Given our
finding of elevated NR4A1 in Daoy cells, NR4A1 may have an oncogenic role in
medulloblastoma, which is supported by our data showing that exogenous overexpression
of NR4A1 promotes Daoy cell viability and proliferation and that NR4A1 knockdown
results in the opposite phenotype.
Upon overexpression of miR-124 in Daoy cells, NR4A1 mRNA and protein
levels and the mRNA levels of NR4A1 target genes decreased, showing that miR-124
affects not only NR4A1 expression but also the transcriptional activity of NR4A1. Stable
overexpression of miR-124 led to decreases in cell viability, cell proliferation, and
microtumor spheroid size, suggesting therapeutic potential for miR-124 in treating
cancer.
Role of NR4A1 in Skeletal Muscle Differentiation
NR4A1 appears to play a variety of roles in muscle, including the enhancement of
glucose and oxidative metabolism in C2C12 mouse myoblasts and in vivo in mouse and

72

rat muscle [148, 474]. In addition, older studies have shown that Nr4a1 expression
increases during C2C12 differentiation [142]. These cells still retained the potential to
differentiate when Nr4a1 was knocked down, however several genes involved in lipolysis
were decreased. This led to the conclusion that NR4A1 is important for energy
expenditure and has potential therapeutic value in treating obesity [142]. More recently,
NR4A1 was found to promote myofiber size and muscle mass in vivo through activation
of the Akt-mTOR-S6K cascade [475]. After global and muscle-specific knockout of
Nr4a1, the muscle mass was decreased. Importantly, primary myoblasts from these mice
formed fewer and smaller myotubes [475]. The above studies were all performed using
either animal models or murine C2C12 cells. We wanted to determine the function of
NR4A1 during skeletal muscle differentiation using human cell lines.
During the differentiation of LHCN, we found that NR4A1 expression increases
by about 4 fold. These results are consistent with previous studies showing a 3-5 fold
increase of Nr4a1 in C2C12 cells [142, 476]. It is of interest to determine which stage
NR4A1 is becoming expressed. Since NR4A1 expression does not increase until Day 3 of
differentiation, it would appear that its presence is not crucial for the initiation of
differentiation. However when NR4A1 was knocked down via siRNA, the induction of
differentiation was severely delayed alongside decreased expression of muscle markers in
LHCN, SkMC, and HSMM. It is also possible that the fusion of myoblasts is being
blocked or delayed. Thus we will need to determine exactly which stage NR4A1 is
playing a role. Nonetheless, this suggests that NR4A1 is important during the
differentiation of skeletal muscle cells.
Previous studies in our lab have demonstrated that the zinc finger transcription
factor ZNF148 (ZBP-89) acts as a suppressor of the myogenic program as deduced from
knockdown studies showing rapid formation of myotubes in LHCN cells when ZNF148
was expressed at extremely low levels. As a well-known repressor of transcription,
ZNF148 is likely acting by binding to the promoters of genes involved in myogenesis and
inhibiting their expression. A recent study links ZNF148 to NR4A1 by demonstrating the
ability of ZNF148 to bind the promoter of NR4A1 and block its expression in pancreatic
β-cells [480]. This discovery led us to question whether ZNF148 is transcriptionally
regulating NR4A1 during skeletal muscle differentiation. Upon knockdown of ZNF148
via siRNA in LHCN cells, NR4A1 expression was rapidly induced by 15 fold along with
high levels of MHC. This suggests that ZNF148 represses NR4A1 in skeletal muscle cells
and that downregulation of ZNF148 by siRNA relieves this repression. To confirm this,
we will need to perform ChIP and probe for ZNF148 at the promoter of NR4A1 in LHCN
cells.
Furthermore, it is unclear whether NR4A1 induction is due to the knockdown of
ZNF148 or as a result of induced differentiation. To elucidate this, we knocked down
both ZNF148 and NR4A1 and tested whether siZNF148 was still able to induce
differentiation. If ZNF148 functions through NR4A1, we would expect abnormal
differentiation in the absence of NR4A1. However, we found that differentiation was still
induced at the same rate (data not shown). Therefore, it would appear that the mechanism
of siZNF148-mediated differentiation is not solely through NR4A1. Since ZNF148 is a
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transcription factor and is known to target and suppress numerous genes, it may still be
acting through NR4A1 in addition to many other genes. Therefore, knockdown of NR4A1
alone would not be sufficient to rescue this phenotype. Another member of the NR4A
family, NR4A3, may be compensating for the lack of NR4A1. Our study among other
studies has shown that NR4A3 increases during skeletal muscle differentiation and
therefore it may have redundant roles with NR4A1 [503]. This would not be out of the
ordinary as other studies have shown overlapping roles for NR4A1 and NR4A3 in other
tissues. It is of interest to determine if NR4A3 expression increases upon NR4A1
knockdown. Perhaps NR4A3 partially rescues the effects of NR4A1 knockdown and
therefore differentiation still occurs, albeit at a slower rate. In addition, a double
knockdown of both NR4A1 and NR4A3 may have a more profound effect on
differentiation by completely preventing the initiation of differentiation. A recent study
found that knockdown of NR4A3 in HSMM blocked the formation of myotubes,
suggesting that NR4A3 is required for skeletal muscle differentiation [504].
The regulation and function of NR4A1 during differentiation is of interest.
Although NR4A1 does not appear to be a mechanism for ZNF148, that does not mean
that ZNF148 is not a mechanism for NR4A1. ZNF148 may need to be suppressed during
differentiation in order for NR4A1 expression to increase. We found that ZNF148 mRNA
levels are unchanged during differentiation (data not shown), however its activity may
still be suppressed. A proteomics study performed in our lab shows that ZNF148 protein
levels decrease by almost 25% during LHCN differentiation (data not shown). Reduced
ZNF148 activity would result in the inability to transcriptionally inhibit NR4A1, which
would result in increased NR4A1 expression. The mechanism by which NR4A1
potentially enhances differentiation is likely through transcriptional activation of genes
important for the initiation and progression of the myogenic program as depicted in
Figure 5-2. NR4A1 has been shown to induce expression of CKM, although it apparently
does not bind the promoter [476]. Furthermore, 685 genes were recently identified by
ChIP-seq as being directly regulated by NR4A1 in AML cells [505]. Interestingly,
NR4A1 was found to transcriptionally activate ENO3 [505], a gene that our lab identified
in the proteomics study to increase by 26 fold during muscle differentiation. ENO3 has
been previously shown to increase during differentiation and has roles during muscle
development [506]. Furthermore, ENO3 was found to be regulated by ETS transcription
factors, which were recently discovered to interact with NR4A1 to transcriptionally
activate NR4A1 target genes [505]. Therefore, it is quite possible that NR4A1 enhances
myogenesis by promoting the expression of genes involved in this process.
It may appear difficult to find a connection between the two main projects
discussed here. The proliferative role of NR4A1 in cancer seems contradictory to its promyogenic role in skeletal muscle. The key to these differential functions may depend on
the expression levels of NR4A1. For instance in cancer, NR4A1 appears to be highly
elevated. This substantial upregulation may be necessary for the proliferative effects of
NR4A1. Conversely, NR4A1 expression increases during skeletal muscle differentiation
(only in LHCN), although not to the same degree as in cancer. During normal muscle
differentiation, NR4A1 may be acting as a co-driver to ensure the smooth and timely
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Figure 5-2. Overview of the myogenic program.
Muscle differentiation begins with mesodermal progenitors that express Pax3 and Pax7.
Transcriptional activity by Myf5 allows the cells to either progress into brown adipose or
into myoblasts after the addition of MyoD activity. Other transcription factors such as
myogenin and possibly NR4A1 allow the cells to become myocytes. These cells fuse into
multinucleated myotubes that will make up the muscle fibers.
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differentiation of skeletal muscle cells, most likely by transcriptionally activating genes
involved in myogenesis.
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APPENDIX. SUPPLEMENTAL DATA FOR CHAPTER 3
Figure A-1. miR-124 decreases NR4A1 expression in miRNA array.
The Cancer miRNAs Transcriptome PCR Array containing cDNA from HeLa cells
transfected with one of the 90 cancer-related miRNAs, as described in Materials and
Methods, was used to detect NR4A1 expression and identify miRNAs that target NR4A1.
The resulting gene expression of NR4A1 is displayed as Log2 with horizontal lines
indicating the cutoff value (as suggested by the manufacturer) at which NR4A1 gene
expression is considered to be significant. Three miRNAs, including miR-124, were
found to decrease NR4A1 expression.
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Figure A-2. NR4A1 and miR-124 have inverse expression in granule neurons.
NR4A1 and miR-124 expression were measured in granule neuron precursors (GNPs)
harvested from P7 mice. The GNPs were cultured for 24 hours, allowing enough time for
the cells to differentiate (GNP diff.) before being collected for expression analysis. The
fold change for the GNPs was set to 1. The internal control for NR4A1 was GAPDH and
the control for miR-124 was snoRNA 202. The data shown are the average of 3
independent experiments with the average Ct values indicated below each graph. *
indicates p < 0.0001.
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Figure A-3. An inhibitor of miR-124 increases NR4A1 activity.
Daoy cells were transfected with the NR4A1-3ʹUTR reporter plasmid (NR4A1-3ʹUTRLuc) and either the Exiqon miR-124 inhibitor at the indicated concentrations or the
control molecule (Cntrl), resulting in increased luciferase activity as the concentration of
the inhibitor increased. Data shown are representative of 2 independent experiments. *
indicates p < 0.05.
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Figure A-4. miR-124 decreases levels of NR4A1 target genes in 293T cells.
Transfection of 293T cells with miR-124 decreased the levels of NR4A1 and its target
genes, E2F1, BIRC5 (survivin), TXNDC5, and CDK4, compared to those of cells
transfected with the vector control (MR03). The data shown are the average of 3
independent experiments. * indicates p < 0.01.
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Figure A-5. NR4A1 knockdown decreases cell viability and proliferation.
(A) Daoy cells were transfected with 20 nM of the individual siNR4A1_4 or nontargeting control (NT), and cell viability was measured via the CellTiter-Glo assay every
day for 4 days. Viability for each day was normalized to that of Day 0 (0 hours), and
statistical significance was calculated for each day; *p < 0.0001. (B) Cells were stained
with crystal violet every day for 4 days to measure proliferation over time. The
absorbance was measured and normalized to that of Day 0 (0 hours). The statistical
significance was calculated for each day; *p < 0.01. (C) Proliferation was monitored via
the IncuCyte live-cell imager. Cell confluence was averaged, with 4 replicates of each
condition; *p < 0.0001. (D) NR4A1 mRNA was significantly (p < 0.0001) decreased after
transfecting Daoy cells with siNR4A1_4. (E) Images shown for each NT and siNR4A1_4
panel over 5 days are the same image view within the same well and are representative of
3 independent experiments with 4 wells for each condition. These images correspond to
the data in C. Data shown in D are the average of 4 independent experiments. Data shown
in A and B are representative of 3 independent experiments, and data in C and E are
representative of 2 independent experiments.
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